Decoding osteoporosis: Understanding the disease, exploring current and new therapies and emerging targets
Article History
-
Received: ,
Accepted: ,
Abstract
Abstract
Bone is a dynamic tissue that is constantly changing and adapting through multiple processes such as osteogenesis, modeling, and remodeling, which usually include the coordinated activities of osteoclasts and osteoblasts. However, a disturbance in this cycle may result in complications with bone health. One of this complication is osteoporosis, a condition that affects globally over 0.2 billion people and causes nearly 90 lakhs fractures yearly. Osteoporosis is a complex disorder impacted by a range of variables, including lifestyle choices, physical activity, genetics, hormonal and endocrine systems, comorbidities (pre-existing diseases), and the use of certain drugs. This article delivers a short overview of the osteoporosis, its diagnosis, and management by non-pharmacological and pharmacological interventions and limitations of existing medications. The review article also highlights both emerging medications and novel targets for preventing and managing osteoporosis, providing a comprehensive look at future therapeutic strategies aimed at protecting bone strength and retarding bone loss. New medications for osteoporosis include romosozumab, cinacalcet and tiliroside. Potential novel targets for preventing bone loss and osteoporosis which are explored in current article include Wnt/β-catenin pathway, fibroblast activation protein, NLRP3 inflammasome, cuproptosis, P2X7 receptor, tumor necrosis factor receptor associated factor 3, Krüppel-like factor, Toll like receptor 4, Yes-associated protein and the transcriptional coactivator with PDZ-binding motif and Sirtuin 3.
Keywords
This article was originally published by Reed Elsevier India Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
1 Introduction
Osteoporosis, a prevalent metabolic and non-communicable skeletal disorder. This condition involves reduced bone mass and an accelerated breakdown of bone microstructure.1 As a result, the bone becomes brittle and more likely to fracture. This ailment often remains undetected until fractures occur, thereby potentially giving rise to severe secondary health complications or even fatality.2 Osteoporosis hits one in three females and one in every five men above fifty years of age.1 It affects about 200 million individuals and causes 9 million fractures globally.3 Bisphosphonates, selective receptor oestrogen receptors, teriparatides, abaloparatide, calcitonin, and monoclonal antibodies are some of the drugs available to treat osteoporosis.3 To accurately manage osteoporosis and other bone metabolism disorders, it is critical to possess comprehensive knowledge of the physical nature of bones, their composition, and the mechanism of their remodeling. Furthermore, understanding the impact of ageing, illnesses, and treatment on bone health is critical.4
This narrative review delves deeply into osteoporosis, its types, causes, and risk factors. The article also emphasizes on the bone remodeling cycle, the comprehensive pathophysiology of osteoporosis, quick overview of diagnosis as well as the presently available osteoporosis therapy. Furthermore, it includes expected novel drugs and therapeutic targets that may be investigated for the discovery of novel therapies to address osteoporosis.
2 Methodology
Databases such as PubMed and Google Scholar were searched without time limitations to find relevant articles for understanding bone remodeling, the pathogenesis and management of osteoporosis, including new possible medications or targets for osteoporosis. The terms and words searched included "bone diseases", "Osteoporosis", "prevalence and epidemiology", "risk factor", "diagnosis", "bone remodeling", "pathophysiology", "Medications for osteoporosis", "management of osteoporosis", "new medications", "new combination", "targets".
3 Osteoporosis
Osteoporosis frequently goes unnoticed until a fracture happens, causing pain and potential disabilities. The aging process typically triggers accelerated bone loss, thereby raising the chances of fractures. Fragility fractures are often associated with osteoporosis and commonly occur in the distal forearm, particularly in the distal radius, because of its susceptibility to low bone mineral density (BMD). The hip is particularly affected due to weight-bearing activities. The spine experiences vertebral compression fractures, leading to pain and posture changes. The distal forearm is vulnerable to fractures from falls or accidents. Other areas like the shoulder, pelvis, and ribs can also be affected. These fractures carry significant consequences, including increased mortality and morbidity rates, as well as a substantial economic burden.5
3.1 Prevalence and epidemiology of osteoporosis
Osteoporosis impacts over 200 million individuals globally, and as individuals become older, the prevalence increases.3 Data reveals that with age, around 33 % of females and 20 % of men who are near or over fifty years old will suffer from osteoporosis.2 In the developed world, male and female prevalence ranges from 2 % to 8 % and 9 %–38 %, respectively. Osteoporosis affects countless people of all genders and ethnicities. However, females, individuals of advanced age, and individuals of Caucasian ethnicity exhibit a higher propensity towards developing osteoporosis.6 Occurrence of osteoporosis heightens the susceptibility to fractures. Osteoporosis causes about 9 million fractures annually throughout the world.3 This global estimate highlights the prevalence of this condition and emphasizes the need for preventive measures and appropriate care for those at risk.1
3.2 Classification, etiology and risk factors of osteoporosis
Osteoporosis manifests itself in two forms: primary and secondary. Primary osteoporosis is chiefly occurring due to ageing while secondary osteoporosis results from underlying diseases or the use of certain medications.2 Type I and Type II are the two main categories into which primary osteoporosis is further divided. Type I is also termed as post-menopausal osteoporosis, which primarily affects individuals aged 50 to 70, and Type II, known as age-related osteoporosis, which mainly impacts those over the age of 70. Type II osteoporosis affects both trabecular and cortical bone structures.3 The ageing process and declining sex hormones are linked to primary osteoporosis.7 Secondary osteoporosis is an outcome of other illnesses or their therapies. Primary osteoporosis more common in female while secondary osteoporosis is substantially more common in male. Glucocorticoids and anti-epileptic drugs are among the medications that can cause secondary osteoporosis.8,9 Additional medications such proton pump inhibitors, thiazolidines, and chemotherapy are also suspected of contributing to osteoporosis, despite their lack of evidence.3 Developing osteoporosis is more likely when exposed to a combination of risk factors, including increasing age, bodyweight below 58 kg, habit of smoking, a family history of this condition, being of Asian or white ancestry, experiencing early onset of menopause, having high inactivity levels, and having a previous fracture resulting from a fall or minor trauma after the age of forty.10,11 Individuals may have a significant reduction in BMD during the first two weeks after sustaining incapacitating traumas, such as spinal cord injuries, particularly if movement is already impaired.12
4 Bone remodeling
4.1 Development of skeletal system
Bone ossification, which is another name for osteogenesis, is the development of new bones. This process normally starts in the embryo's sixth or seventh week of growth and lasts until around twenty-five years of age, however unique situations may create variances among people.13 There are two bone ossification types which are intramembranous and endochondral. Both of these start by the emergence of mesenchymal tissue precursor, but the way they transform into bone differs.13 In the case of intramembranous ossification, the process entails the substitution of membranous connective tissue sheets with osseous tissue. In this type of ossification, the mesenchymal tissue directly converts into bone. This process of ossification results in the flat bones development, including those present in the skull, clavicle, and cranial bones.14 In embryonic connective tissue, mesenchymal cells proliferate in vascularized regions, forming cell condensation or primary ossification centers. The cells in the outer region synthesize the bone matrix while others differentiate into osteoblasts. The bone then undergoes remodeling and is eventually replaced by lamellar bone.15 The initiation of endochondral ossification, however, entails the conversion of mesenchymal tissue into an intermediate cartilage stage, subsequently substituted by bone, thereby facilitating the growth of the axial skeleton and elongated bones.13,16
4.2 Process of bone remodeling
The skeletal structure of humans is not made up of static bones, as they undergo continuous changes during the course of an individual's life. Bone remodeling is referred to the process by which the structural stability of the skeletal system is upheld by carefully maintaining the levels of the phosphorus and calcium in the body. This process involves removing damaged or weakened bone tissue17. Bone remodeling is executed through the cooperation of various kinds of cells like osteoblasts that line the bone, osteoclasts, and osteocytes is essential for the successful completion of this procedure.18 The skeletal structure is always changing through modeling and remodeling. The formation and resorption process can independently modify the size or shape of skeletal elements in modeling. For instance, long bones can enlarge through periosteal apposition and endosteal resorption.19 Remodeling involves resorption and formation at the same site. This process can be balanced, with equal number of new bones formed and resorbed, or imbalanced, resulting in bone gain or loss. Both modeling and remodeling processes are structured by a combination of both local and systemic elements, which ultimately dictate the equilibrium between the resorption of damaged and aged bone and the development of new bone.20 This process consists six phases: i) activation, ii) reabsorption, iii) reversal, iv) formation, v) mineralization, vi) quiescence.21 The steps of bone remodeling cycle is shown in Fig. 1.

4.2.1 Activation phase
The bone surface is activated by regenerative stimuli, and stem cells transform into osteoclasts.22 During the initial stage of activation, interaction between osteoclasts precursor cells and osteoblasts takes place. Large multinucleated osteoclasts undergo differentiation, migration, and fusion, leading to their subsequent adherence to the mineralized surface of the bone.23
4.2.2 Reabsorption phase
This phase involves attachment of osteoclasts on the outermost layer of mineralized bone. Bone lining cells cover the mineralized bone. However, osteoclasts need uncovered surface to adhere on mineralized bone. This necessitates alterations in the cells that line the outermost layer of bone and wrap it. They constrict and release proteolytic enzymes thus exposing the mineralized surface.23 Once osteoclasts adhere to the surface of bone, it initiate the resorption process by the production of hydrogen ion and lysosomal enzyme. Bone matrix degradation, including the breakdown of collagen, is specifically mediated by cathepsin K in an acidic environment. The process facilitated by macrophages involves the discharge of growth factors embedded within the matrix. These growth factors comprise of Insulin-Like Growth Factors I and II (IGF-I and II), Transforming Growth Factor Beta (TGF-β), and Platelet Derived Growth Factor (PDGF). These growth factors are responsible for playing a critical role in controlling several cellular mechanisms that contribute to tissue repair, wound healing, and angiogenesis.21
4.2.3 Reversal phase
This phase begins after the osteoclasts have finished their task of removing bone. In the reversal phase mononuclear cells, potentially of the macrophage lineage, are observed on the surface of the bones. The precise mechanisms that take place during this stage remain unclear, but they could potentially entail additional breakdown of collagen. This phase also includes synthesis of proteoglycans which further results in the construction of the cement line and the discharge of growth factors which further initiates the formation phase.23
4.2.4 Formation phase
In this stage, osteoblasts do gradual replacement of resorbed bone through the deposition of new bone, ultimately leading to complete substitution.19 Preosteobslasts tend to group together in the areas where resorption is taking place, as they are drawn towards the growth factors that are being emitted from the matrix. These growth factors not only act as chemotactic agents, but also encourage the preosteoblasts to multiply.24 A material is produced by the preosteoblasts that acts as a binder for the newly formed tissue, facilitating its attachment. Additionally, bone morphogenic proteins (BMP) are expressed by these preosteoblasts, which are essential for cellular differentiation. After a brief duration, the differentiated osteoblasts initiate the synthesis of osteoid material, effectively filling the perforated regions.23
4.2.5 Mineralization phase
Mineralization initiates one month subsequent to the deposition of the osteoid, finishing after a span of 90-day in case of trabecular bone, while the cortical bone takes 130 days to complete its cycle.23 During bone formation, the introduction of calcium phosphate nanocrystals in organic bone matrix is known as bone mineralization. This process takes place in a well-organized, precise manner, and is regulated by the osteoblasts. Furthermore, the organic osteoid matrix formed by osteoblasts serves as the exclusive site for this process. The osteoid matrix is a essential element in the development of bones, consisting primarily of collagen and other proteins. Osteoblasts secrete this matrix, which subsequently becomes mineralized to form mature bone tissue. The growth factors released within this matrix, like TGF-β, PDGF, and IGF-I and II, play pivotal part in regulating the activities of osteoblasts and other cells engaged in the synthesis of bones and remodeling. This orchestrated release and action of growth factors within the osteoid matrix are essential for appropriate bone formation and maintenance.25
4.2.6 Quiescence phase
During the process of bone remodeling, the term "quiescent phase" denotes a period in which bone cells, specifically osteoblasts and osteoclasts, exhibit a state of reduced activity or rest.23 In this final phase, quiescence, signifies the bone's return to normal function until the next remodeling cycle.22
5 Pathophysiology of osteoporosis
Osteoporosis exemplifies a multifactorial condition, wherein an intricate interplay of various factors, such as genetics, inherent characteristics, external influences, and lifestyle choices, collectively impact an individual's vulnerability to the illness.26 Traditional pathophysiologic models of postmenopausal osteoporosis focus on the primary endocrine changes that drive bone loss. These endocrine changes include estrogen insufficiency after menopause and secondary hyperparathyroidism in older individuals. These mechanisms are associated with other factors such as reduced food consumption, common vitamin D deficiency, and the pre-existing diseases.27 Furthermore, a frequent side effect of long-term corticosteroid treatment is osteoporosis, which may result from increased bone resorption and disruption in bone remodeling.28 Secondary osteoporosis also occurs due to long term usage of several drugs like proton pump inhibitors, anti-epileptics, selective serotonin reuptake inhibitors etc.
5.1 Hormone induced osteoporosis
Hormone associated osteoporosis is a significant condition influenced by hormonal imbalances. In women during menopause, estrogen deficiency contributes to higher resorption of bone and decreased BMD.29 Lack of estrogen impacts bone health in two key ways. Firstly, it enhances the production of osteoclasts and prevents their natural death, which increases the breakdown of bone tissue. Secondly, it increases the production of inflammatory substances like interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFα), and prostaglandin E2, causing a surge in the production of immature osteoclasts in the bone marrow.30 Additional to estrogen deficiency, condition such as hyperthyroidism, characterized by elevated parathyroid hormone (PTH) levels, also contributes to osteoporosis by promoting bone resorption.31
5.2 Drug induced osteoporosis
There are various medications which can gradually contribute to osteoporosis.
5.2.1 Glucocorticoids
Glucocorticoids are commonly used to treat various diseases, but they can negatively impact bone health. Numerous studies have shown that individuals receiving chronic glucocorticoid treatment have a fracture incidence ranging from 30 % to 40 %, with the risk being influenced by the dosage of the medication.32 However, stopping the treatment can normalize the fracture risk. Reports indicate that glucocorticoids impair bone formation by negatively affecting osteoblasts, osteocytes, and osteoclasts. These consequences throw off the equilibrium of bone remodeling, which reduces bone density and elevated the chances of fracture.33
5.2.2 Proton pump inhibitors
Studies have shown a correlation between the prolonged utilization of proton pump inhibitor medications and a higher chance of fractures. This association is principally attributed to two main processes. Firstly, hypergastrinemia causes the activation of osteoclastic precursors, leading enhanced bone resorption. Additionally, the reduced stomach acid levels in hypochlorhydria have an impact on the assimilation of magnesium and calcium, which leads to hyperparathyroidism and heightened activity of osteoclast. These factors together increase the likelihood of fractures by impacting bone remodeling, reducing mineral absorption as well as muscle strength and inducing physical instability.34
5.2.3 Antiepileptic drugs
Numerous researches have provided evidence that utilization of antiepileptic medications raises the chances of fractures in any area of the body by 86 %. In addition, it augmented the likelihood of hip fractures by 90 %.35 The risk is particularly elevated in individuals who take antiepileptic drug that induce liver enzymes, compared to those that do not. Examples of such antiepileptic drugs include thiobarbiturates, topiramate, and phenytoin. The activation of orphan nuclear receptors and pregnane X factor (PXR) by antiepileptic drug in the gastrointestinal tract, liver, and kidneys have a crucial function in modulating the drug's pharmacokinetics and pharmacodynamic. Furthermore, they trigger CYP450, which ultimately enhances the vitamin D breakdown and converts it into its inactive forms. Low vitamin D causes a attenuation in calcium levels in the bloodstream and secondary hyperparathyroidism.36
5.2.4 Systematic hormonal therapy
Aromatase inhibitors are used as a hormone replacement medication for breast cancer treatment. They may cause estrogen levels to drop, which may have an undesirable impact on bone health and promote the loss of bone.37 The deteriorations of bone triggered by aromatase inhibitor usage is twice as much as the natural bone loss experienced after menopause.38 Additionally, gonadotropin releasing hormone (GnRH) agonists like leuprolide is utilized to treat hormone-sensitive malignancies such prostate and breast cancer in males and premenopausal women. It also helps to manage endometriosis and uterine fibroids symptoms. GnRH agonists act by interacting with GnRH receptors in the pituitary gland, effectively inhibiting the secretion of gonadotropins including luteinizing hormone and follicle stimulating hormone. This inhibition reduces the formation of sex hormones (testosterone and estrogen) which further induced attenuation in bone density and augmenting the chances of osteoporosis and fractures. Osteocytes, osteoclasts and osteoblasts, have receptors for androgens and estrogens, making them receptive to hormonal signs. The decline in these hormones results in a disturbance in cellular function and impacts the bone remodeling process by stimulating bone resorption rather than formation.39
5.2.5 Selective serotonin reuptake inhibitors
Serotonin receptors can be found in osteoblasts and osteocytes. Serotonin has significant involvement in the control and communication of bone remodeling activities. An investigation involving women, a higher occurrence of non-spinal fractures was observed in elderly patients, who have been prescribed SSRIs.40 Furthermore, a decline of 3.9 % in BMD was noted in elderly males who utilized SSRIs, in contrast to individuals who consumed tricyclic antidepressants or did not take any antidepressants.41 The precise mechanics behind the connection between heightened fracture risk and the use of SSRI medications are not yet completely understood. It is hypothesized that the interference with serotonin receptors in bone cells may lead to changes in signaling pathways that promote bone resorption.42
5.2.6 Loop diuretics
Loop diuretics are frequently prescribed and utilized among the elderly population. Their main mechanism of action involves enhancing the reabsorption of chloride and sodium specifically at the Henle's loop, while also decreasing calcium levels. Loop diuretics reduce the reabsorption of calcium and promote its excretion. This can potentially lead to hypocalcemia, which can in turn results in decreased BMD.43 However, the depletion of renal resorption of calcium induced by loop diuretics could be counterbalance by the rise in the vitamin D activity, which is dependent on parathyroid hormone (PTH) and assists in preserving adequate calcium levels in the body.44 Nevertheless, it is crucial to highlight that extensive research and controlled trials are necessary to delve deeper into these impacts.
5.3 Disease induced osteoporosis
Various disease conditions and metabolic disorders which can slowly directly or indirectly contribute to osteoporosis.
5.3.1 Thyroid disease
Hyperthyroidism may cause increased bone turnover and development of osteoporosis. Osteoporosis in addition to underlying thyroid disorder, such as hyperthyroidism, can also result from excessive administration of levothyroxine, a medication used to treat hypothyroidism. These factors are connected to decreased BMD and a heightened likelihood of experiencing hip and vertebral fractures.45–47 On the other hand, hypothyroidism is linked to a decrease in both the creation and breakdown of bones, and it seems to have no effect on the likelihood of fractures. Nevertheless, women who have entered menopause and are diagnosed with subclinical hypothyroidism have been recognized to experience an increased susceptibility to fractures.45
5.3.2 Chronic kidney disease
As chronic kidney disease (CKD) progresses, it impacts bone health significantly, leading to conditions like osteoporosis and renal osteodystrophy. This is primarily due to the kidneys' reduced ability to convert and activate vitamin D into its functional form, calcitriol. Calcitriol is crucial for calcium absorption from the diet; without it, blood calcium levels drop. In response, the parathyroid glands elevate the formation and release of parathyroid hormone (PTH) to raise calcium concentration in the blood. Elevated PTH concentratiom, in turn, cause increased bone resorption, where calcium is extracted from bones to maintain blood calcium levels. Over time, this process weakens the bones, contributing to the development of osteoporosis and renal osteodystrophy. Managing CKD effectively involves addressing these complications through medications, dietary adjustments, and sometimes vitamin D supplementation to support bone health and prevent further damage.48
5.3.3 Diabetes
Diabetes is related with a greater risk of low-energy fractures (occur with minimal trauma) because of their association with diminished bone strength and quality. Highlighting the importance, it is essential to stress that type 1 diabetes mellitus (T1DM) directly results in a lowering of BMD. People with T1DM face an increased likelihood of fractures, specifically in the hip region. This risk remains substantial, even when considering the presence of additional health conditions like CKD.49,50 Insulin and IGF-1 have significant roles in bone growth and development. Therefore, insufficient levels of insulin and IGF-1 in T1DM are believed to partially contribute in increased susceptibility to fracture.51 T1DM occurs in adolescence and early adulthood, when bone formation is crucial. This condition may lower BMD, emphasizing the need to boost BMD and peak bone mass. Proper diet, especially calcium and vitamin D, weight-bearing activity, and glycemic management are essential. These strategies may lower the risk of osteoporosis and fractures in patients with T1DM. Type 2 diabetes mellitus (T2DM) does not lower BMD, but it increases the risk of hip, vertebral, and other fractures.49 It presents a difficulty for elderly individuals since the conventional assessment of BMD might undervalue the higher chances of fractures in patients with T2DM. Enhanced mechanical loading, such as that from obesity, can stimulate bone formation by increasing the stress placed on bones, which promotes bone density and strength. Similarly, hormonal factors like hyperinsulinemia can influence bone health, as insulin is involved in bone metabolism. However, while increased mechanical loading generally benefits bone formation, the effects of obesity and hormonal imbalances can be complex, sometimes leading to mixed outcomes for bone health.52 Hence, there exist supplementary factors that contribute to the elevated susceptibility to fractures in individuals with T2DM. Patients suffering from chronic hyperglycemia, for instance, experience increased production of advanced glycation end-products. These final results obstruct the bonding of collagen in the bone framework, resulting in decreased strength and quality of the bones. Moreover, individuals with diabetes are also more prone to experiencing falls.53 This can be ascribed to various factors including peripheral neuropathy, reduced physical capability, orthostatic hypotension, impaired vision, and even hypoglycemia caused by medication.
5.3.4 Presence of osteosarcopenia
Osteosarcopenia is a condition defined by the simultaneous development of osteoporosis and sarcopenia. Osteoporosis is connected with decline in bone mass and density. On the other hand, sarcopenia is a degenerative condition in muscular tissue that reduces muscle mass, strength, and function.54 Sarcopenia can be manifested as primary sarcopenia due to aging or as secondary sarcopenia resulting from other underlying illnesses like diabetes. Sarcopenia, like osteoporosis, is caused by multiple factors, including poor diet, increased age, decreased physical activity, inflammation, and concomitant disorders. Osteoporosis is primarily diagnosed through the measurement of BMD by utilization of techniques such as Dual energy X ray absorptiometry (DXA). In contrast, sarcopenia diagnosis entails the assessment of muscle strength, function, and lean mass.55 Muscle strength can be assessed by various measures such as hand grip strength, while function can be evaluated by analyzing chair rise time or walking speed. When osteosarcopenia is suspected, DXA is required to determine lean and total appendicular mass as well as BMD.55
Bone and muscle share a common developmental origin from mesenchymal tissue, indicating a close relationship in their development.56 Because of this shared origin, they are influenced by similar factors that help maintain homeostasis, and changes in one can affect the other, highlighting their interconnectedness. Genetic variations, such as those in androgen and estrogen receptors, IGF-1, and the vitamin D receptor, play a significant role in this balance.57 Aging affects both the biological and chemical interactions between bone and muscle, leading to reduced physical activity and mechanical stress. This results in decreased functionality, bone mass, and BMD.58 The "Mechanostat hypothesis" proposes that bone formation is stimulated rather than bone resorption when mechanical forces from muscles on the bone surface exceed a certain threshold, aligning with current understanding. Additionally, aging often leads to a decrease in vitamin and protein intake, which results in weakened muscle strength and compromised bone mineralization, thereby raising the possibility of falls.59
6 Diagnosis and assessment of risk of osteoporosis
DXA scan is used to assess the BMD of the upper thigh bone in order to detect osteoporosis. This examination offers a T-score, which reflects BMD that is significantly less than the typical amount for a healthy, young adult. A −2.5 T-score or lower identifies osteoporosis.57 It is critical to take note of that most breaks happen in people with osteopenia, which is described by a T-score between −1.0 and −2.5. These diagnostic criteria are examined together with additional risk factors and patient preferences when choosing a lifestyle and therapy. In older individuals, interpreting DXA results requires accounting for factors such as degenerative spine disease, vertebral compression fractures, and herniated discs. Degenerative spine disease is where thinning discs and reduced impact absorption may affect measurements. Vertebral compression fractures, where collapsed or broken vertebrae can alter BMD readings and herniated discs is where the protrusion of the inner disc core through its outer layer can lead to false increases in BMD measurements. Moreover, in situations of osteomalacia, which is often associated with malnutrition in older persons, the total bone matrix is compromised, resulting in an undermining of BMD in DXA examinations.60
Measurement of femoral neck's BMD is a primary method for investigating osteoporosis. Multiple techniques are available to assist healthcare practitioners in providing a more exact evaluation of the possibility of fracture and making educated choices regarding its prevention and treatment. Another method for estimating fracture risk is the Fracture Risk Assessment Tool (FRAX), designed by the World Health Organization (WHO). This gives an estimate of the likelihood of experiencing a fracture associated with osteoporosis in the next 10 years.61 Other tools for assessing the risk of facture are quantitative computed tomography (QCT) and trabecular bone score (TBS). TBS assesses bone texture and density as well as bone microarchitecture, which aids in determining bone quality. In contrast, QCT provides a complete 3D assessment of bone density and distinguishes between trabecular and cortical bone. The QFracture clinical algorithm is used to predict fractures based on a variety of clinical risk variables. It considers age, gender, medical history, and lifestyle patterns. Furthermore, technologies such as FRAX have shown reliability in predicting fracture risk and monitoring bone health by combining clinical risk factors with BMD tests. Together, these measures provide a comprehensive method for assessing fracture risk and bone health.62 It should be noted that risk calculators provide only a chance of risk rather than a particular therapy recommendation. Irrespective of the healthcare setting, treatment decisions should prioritize the patient's choices and involve coordinated decision making. The existence of other illnesses, usage of several drugs, and social and psychological variables should be evaluated. It is critical to highlight that the FRAX score does not take into account the risk of fractures, which is impacted by variables such as corticosteroid use, smoking, and alcohol usage. It is crucial to note that the influence of these substances may also differ depending on the amount taken. Moreover, these tools sometimes overlook the significant risks associated with having multiple previous fractures, which can be a clear indicator of increased bone fragility. Therefore, it is essential to consider the complexities of these factors when assessing fracture risk among older adults.60 Implementing a screening plan for fracture risk behaviors in high-risk individuals is crucial for proactively improving outcomes after traumatic breaks. For instance, the FRAX tool can identify postmenopausal women aged 70 to 85 who are at high risk and may benefit from medication for fracture prevention.63 An old individual admitted for a hip fracture would sometimes have signs of the osteoporosis, sarcopenia, and a lot more signs of physical weakness. In this scenario, their evaluation procedure and treatment need the efforts of many experts, such as orthopedic physicians, geriatric teams, pharmacists, therapists, nurses, psychiatrists, nutritionists, and speech and language specialists. The care should be guided by the comprehensive geriatric assessment process.64 Recently, there has been a growing focus on the concept of impending fracture, which identifies those who are at the extreme risk of developing a fracture within two years after a first fracture. Such occurrences may occur in up to 23.2 % of patients.65 Multiple factors can rise the likelihood of fractures, including previous fractures, the location of the fracture, advanced age, osteoporosis, and other medical conditions such as cognitive impairment. Additionally, polypharmacy affecting the central nervous system, reduced physical activity, overall poor health, and a history of previous falls also contribute to a greater likelihood of fractures.66 It is of utmost importance to expeditiously identify, assess, and provide necessary care to individuals with the highest risk using the Fracture liaison service model. This approach aims to mitigate the potential repercussions of fractures in the forthcoming period.67
7 Management of osteoporosis
In the initial phase, the management of osteoporosis focuses on nonpharmacological treatment options. This involves recommending exercise to enhance overall bone's health and strength. The osteoporosis management is also significantly influenced by diet.68 A diet packed with calcium and vitamin D is necessary to keep bones strong.69 These nutrients can be obtained from various food sources, including milk, cheese, yogurt, leafy greens, and fortified cereals. In special situations, dietary supplements may be advised to guarantee adequate consumption.70 Two additional significant lifestyle modifications to treat osteoporosis involve avoiding smoking and limiting alcohol consumption to moderate level. It is recommended that women consume no more than one alcoholic beverage per day, while men should limit their intake to a maximum of two drinks daily.71 After using nonpharmacological options, the next step is to propose specific drugs for osteoporosis management. There exist two primary classifications of medications: anti-resorptive drugs (anti-catabolic) and anabolic drugs. Anti-resorptive drugs function by diminishing the speed at which bones are deteriorated, lowering bone resorption, and halting additional bone loss. Bisphosphonates, selective estrogen receptor modulators (SERMs), and denosumab are commonly recommended medications to prevent the loss of bones.72 Anabolic drugs, in contrast, promote the growth of fresh bone tissue, resulting in higher bone density. Teriparatide is an artificial form of parathyroid hormone. It is the most often given anabolic drug for osteoporosis.73 A medical expert may recommend a mix of medications in certain circumstances to effectively manage osteoporosis. This might include taking anabolic and anti-resorptive medications together, or additional medications tailored to the specific needs of the patient. Consistent monitoring, such as bone density scans, is necessary for determining the success of therapy.74 The details of non-pharmacological and pharmacological treatments are explained below.
7.1 Non-pharmacological management
Physical activity and exercise are well-documented methods for preventing osteoporosis and reducing the chance of falls and fractures. Resistance training stands out among exercise techniques for its ability to sustain skeletal muscle while also promoting bone development and strength. Thus, increasing BMD and minimizing the risk of osteoporosis. This comprehensive approach to fitness emphasizes integration of resistance training into regular workout routines for these health benefits.75 Regular exercise, particularly strength training, might avoid abrupt deterioration and postpone frailty syndrome by improving BMD and reducing the chances of falls and fractures. This proactive strategy helps older persons retain strength and stability, improving quality of life and independence.76 Studies indicate that high-impact exercise is the most efficient way to boost BMD in the femoral neck. Engaging in strength training that focuses on the lower limbs has been proven to yield optimal outcomes.77 Moreover, addressing issues with the abdominal core's biomechanics and enhancing hip flexion and knee extension can help decrease the chances of falls and relieve musculoskeletal pain.78,79 Certain lifestyle changes may prevent osteoporosis. These changes involve quitting smoking, limiting alcohol, getting adequate calcium from food, and eating a balanced diet with plenty of fruits, vegetables, and protein.70,80
Vitamin D enhances calcium, magnesium, and phosphate absorption in the intestines. Vitamin D occurs in two main types i.e., D2 and D3. D2 comes from plants and D3 is produced in human skin and obtained from animal-based foods. As shown in Fig. 2, Vitamin D transforms into calcitriol, this calcitriol inhibiting parathyroid genes and cells and increases serum calcium levels. Calcitriol affects the intestine, kidneys, and bone to control calcium levels. It promotes bone mineralization by activating the vitamin D receptor signaling pathway in osteoblasts. However, high calcitriol may hinder mineralization by altering the activity of osteoclasts and osteoblasts.81

To maintain good bone health and avoid deficiencies, it is typically suggested to consume more than 800 IU of vitamin D daily, as well as 700–1200 mg of calcium each day. Individuals aged 50 and above, regardless of gender, may greatly lower the likelihood of falls by following the recommended vitamin D intake. In cases where there is a higher risk of fractures, the vitamin D dosage can be further increased. Nevertheless, caution should be taken when recommending occasional massive dosage of vitamin D (≥100,000 IU). Studies have established a correlation between such high doses and an amplified probability of falls and fractures.82 Patients undergoing bone-focused therapy need both calcium and vitamin D to completely benefit from these treatments, as shown in intervention trials. This combination not only improves the efficacy of bone medicines, but it also prevents secondary hyperparathyroidism, hypomagnesaemia, and bone metabolism disorders.83 Taking vitamin D with food that contains fat enhances its bioavailability.84
7.2 Pharmacological management
Numerous medicinal therapies have been devised to mitigate the likelihood of fractures and avert the decline in bone density. Osteoporosis is commonly treated with various medications such as bisphosphonates, SERMs, monoclonal antibodies like denosumab, anabolic substances like teriparatide and abaloparatide, and calcitonin. All of these therapies function via distinct mechanisms to prevent bone loss and stimulate bone development.74Fig. 3 illustrates the mechanism of action for all available class of drugs.

7.2.1 Bisphosphonates
Bisphosphonates are commonly prescribed first line drugs for osteoporotic patients. These medications function by blocking the action of farnesyl diphosphate synthase enzyme, which is responsible for controlling G-proteins and regulating osteoclast function, thereby attenuating bone resorption and helping to maintain bone density.85 Examples of drugs of this class are Etidronate, clodronate, and tiludronate. Nitrogen side chain-containing bisphosphonates, known as amino bisphosphonates, belong to the second and third generations of bisphosphonates. These nitrogen side chains are responsible for the binding of the drug and deactivation of farnesyl pyrophosphate synthase, which further inhibits the mevalonic acid pathway. This interruption hinders the completion of posttranslational modifications in proteins, leading to the apoptosis of osteoclasts. Consequently, this process reduces bone resorption and helps in maintaining bone density. Alendronate, ibandronate, pamidronate, risedronate, and zoledronic acid falls under the category of second-and third generation bisphosphonates. Moreover, these categories of medications differ in their target cells. Nonnitrogen-containing bisphosphonates can influence mammalian cells with farnesyl pyrophosphate synthase expression, while nitrogen-containing bisphosphonates induce program cell death in osteoclasts by explicitly targeting bone mineral specifically hydroxyapatite. This binding of nitrogen-containing bisphosphonates with bone mineral allows them to remain in the bone matrix for extended periods.86 Therefore, even though bisphosphonates have a short time in the bloodstream, they can still be present in bones for many years.87 Several studies have shown that alendronate can reduce 50 % fractures of wrist, hip and spine. In contrast, the utilization of risedronate can result in a 40 % reduction in both vertebral and nonvertebral fractures over a span of three years. However, administering zoledronic acid intravenously has showed an amazing reduction in spine fractures by 70 % and hip cracks by 40 % over a three-year period.88 Oral administration of bisphosphonates is possible after an extended period of fasting, accompanied by water intake and refraining from any other oral intake for 30–60 min. Alternatively, bisphosphonates can be given intravenously.89
7.2.1.1 Alendronate
Alendronate must be consumed after an overnight fasting period and 30 min before having breakfast (and taking any other medications) or beverages (except water). The prescribed dose is either 70 mg orally once a week or 10 mg daily. A lower dose is recommended for preventing glucocorticoid-induced osteoporosis and is also successful in treating postmenopausal osteoporosis in women. It is additionally utilized for treating osteoporosis in males. Overall, this medicine is necessary to uphold bone health and lessen the chances of osteoporosis and fractures in various patient populations. It has proven to be more effective in preventing vertebral and hip fractures.90 During the administration of this medication, it's important to maintain a standing position for 30 min to decrease the chances of any adverse effects in the upper digestive system.91
7.2.1.2 Risedronate
Risedronate is a drug of third-generation bisphosphonate class.90 The medication has been authorized for treating osteoporosis in women who have gone through menopause, as well as in men with osteoporosis who have a high probability of experiencing fractures. Moreover, it is recommended for patients who are using glucocorticoids. Taking either a weekly oral dose of 35 mg or a daily 5 mg dose has demonstrated the drug's effectiveness in reducing vertebral and hip fractures.92 Oral drugs often reduce treatment efficacy owing to adverse effects, poor absorption, and administration manner. Additionally, pre-existing health issue, the need for multiple concurrent medications, and the deterioration of functional abilities in the older patients further complicate this situation.93
7.2.1.3 Zoledronate
Zoledronate which also known as zoledronic acid, is given through an intravenous (IV) route. This particular drug is utilized as an antiresorptive agent for treating diverse bone conditions, encompassing osteoporosis, Paget's disease of bone, and bone metastases in cancer patients.94 Zoledronate, directed intravenously, is prescribed for patients who can't endure or have contraindications to oral bisphosphonates. Also, it tends to be considered as the first-line treatment for forestalling postmenopausal osteoporosis and for those at expanded chance of fractures.95 The management of inorganic pyrophosphate levels in hydroxyapatite crystals in bone is critical for the onset of new bone formation. Bisphosphonates which contain nitrogen, like zoledronate, exhibit a higher affinity towards inorganic pyrophosphate and specifically bind to regions of bone undergoing active remodeling. These bisphosphonates are emitted by osteoclasts upon the breakdown of bone and absorbed by the osteoclasts, limiting their activity and thereby lowering bone resorption. Bisphosphonates also inhibit an enzyme, farnesyl diphosphate synthase in the HMG-CoA reductase pathway that synthesizes lipids, cholesterol, and sterols, in osteoclasts. This inhibition impairs critical biological activities inside the osteoclasts, resulting in its decreased activity and death. Bisphosphonates block farnesyl diphosphate synthase, preventing the prenylation of small GTPase signaling proteins. Thus, it blocks the pathway that prompts changes in critical small proteins important for the activity and lifespan of osteoclasts. Reduced osteoclast activity and mortality leads to less bone resorption and thus, contributes to preserve bone density. Zoledronate does not affect the movement of osteoblasts or the mechanics of bone formation. Thus, it alters the equilibrium of bone metabolism, resulting in an augmentation in bone mass and density as the pace of bone growth surpasses that of resorption. This is a main reason behind stronger bones and reduced chances of fractures in osteoporosis and other bone-related diseases.86
7.2.2 Monoclonal antibody
Denosumab, a human monoclonal antibody that blocks the RANKL (receptor activator of nuclear factor kappa-Β ligand). RANKL is a crucially involved in the production and activation of osteoclasts. Denosumab's mode of action targets bone loss caused by stresses such as estrogen shortage during menopause. In response to a decrease in estrogen, osteoblasts and osteocytes generate the RANKL protein. RANKL interacts with the RANK receptor on the osteoclasts and its precursors. This interaction trigger osteoclast, the cells responsible for bone resorption. Activated osteoclasts damage bone tissue by releasing enzymes that break down bone components like collagen. In a normal physiology, the protein osteoprotegerin (OPG) binds to RANKL, blocking it from interacting with RANK on osteoclasts. This binding inhibits osteoclast activity and prevents bone resorption. Denosumab behaves similarly to OPG. It interacts to RANKL, suppressing it from activating its receptor on osteoclast cells. This inhibition lowers osteoclast production, function, and survival, which in turn prevents resorption of bone. As a result, bone mass and density increase because bone growth surpasses bone resorption. Initially approved in 2010 under the brand name Prolia. This is and alternative therapy for patient's incapable of taking oral medications or have an increased risk of complications, and it is administered subcutaneously at regular intervals by a clinical specialist. It is crucial to emphasize that the possible negative impacts of denosumab therapy include weakness and fatigue. Several clinical studies have shown that denosumab is more efficacious than calcium and vitamin D supplementation in lowering the incidence of hip, vertebral, and non-vertebral fractures.96 Denosumab showed a significant 68 % lessening in radiographic vertebral cracks, 40 % decrease in hip breaks, and 20 % reduction in non-vertebral breaks in postmenopausal women.97,98 Patients must smoothly switch to oral bisphosphonates after stopping denosumab or other anabolic treatments to prevent further bone deterioration.99
7.2.3 Selective estrogen receptors modulators
Selective estrogen receptor modulators (SERMs) are synthetic ligands intended to selectively bind with the estrogen receptor. These synthetic ligands have been approved for preventing and treating osteoporosis in women (postmenopausal). SERMs, as opposed to estradiol, prompt an unmistakable natural response that results in the apoptosis of osteoclasts. Raloxifene, lasofoxifene, and bazedoxifene are the SERMs that have received authorization for osteoporosis treatment.26 Estrogens and SERMs exerts significant influence on the skeletal system, effectively averting loss of bone and reducing the chances of getting fractures. When it comes to enhancing bone strength and lowering the likelihood of fractures, hormone treatment at full dosage outperforms SERMs. Low-dose and transdermal hormone therapy has become more popular. Nevertheless, SERMs exhibit a diminished impact on bone density and fracture susceptibility as a result of their partially opposing actions on the estrogen receptor. SERMs have benefits over estrogen in terms of minimizing certain adverse effects and exhibiting opposing effects in other contexts. Each SERM has different activities in specific tissues. The variable effects of SERMs on specific tissues have hindered their clinical application.100
7.2.3.1 Raloxifene
Raloxifene is one of the SERM, a medication that mimics estrogen and attaches to estrogen receptors, activating estrogenic pathways in certain tissues while blocking estrogen action in others. For instance, in bone, it activates estrogenic pathway and promote bone density, while antagonizing estrogen in tissues for instance the uterus and breast. The two isoforms of estrogen receptors, alpha and beta, can affect how cells respond to estrogens. Raloxifene aids in the fall of bone resorption in postmenopausal osteoporosis, causing an augmented bone thickness and strength, ultimately lowering the risk of fractures. Raloxifene not only helps in managing bone health but also contributes to improving cardiovascular health, potentially lowering the possibility of heart disease. It improves cardiovascular health by decreasing levels of low-density lipoprotein cholesterol (LDL-C), fibrinogen, and lipoprotein(a). Raloxifene is suggested for postmenopausal women who have a high chances of invasive breast cancer or those with osteoporosis. High risk is determined by factors such as a family history of breast cancer, specific findings on a breast biopsy, or a 5-year estimated likelihood of breast cancer exceeding 1.66 %. By targeting both bone health and breast cancer risk, raloxifene provides dual benefits for these women.101
7.2.4 Parathyroid hormones analogues
Abaloparatide and teriparatide have been licensed to treat osteoporosis. These drugs are synthetic versions of parathyroid hormone (PTH), which is crucial for retaining calcium balance and encouraging bone development and density. Teriparatide is specifically authorized for both female and male patients of osteoporosis and who are more susceptible to fractures. It is also approved for those who have developed osteoporosis as a result of prolonged glucocorticoid treatment. Administering intermittent low-dose injections of teriparatide effectively enhances bone growth. It stimulates osteoblast activity when given intermittently, leading to new bone formation. New bone formation surpasses the resorptive action of osteoclasts, which release calcium and phosphorus from bones, resulting in a net upsurge in bone density and strength. The mechanism outlined above renders it a very effective therapy for osteoporosis.26
7.2.5 Calcitonin
Calcitonin treats osteoporosis by inhibiting osteoclast activity, reducing bone resorption, and providing an analgesic effect, which helps to preserve bone density and reduce likelihood of fracture. It is a viable treatment option for individuals with Paget disease of bone who are unable to tolerate bisphosphonates. This medication has been clinically proven to alleviate bone pain, reverse neurological deficits, decrease blood flow to the affected bone, and potentially improve hearing loss associated with Paget's disease. Unlike bisphosphonate therapy, which requires three months to achieve maximum suppression of bone resorption, calcitonin therapy reaches its peak impact on osteoclasts within 24–48 h. This particular characteristic makes calcitonin the preferred choice in situations where immediate surgery on the affected bone is necessary.102
7.3 Limitations of current medications for osteoporosis
Bisphosphonates, including alendronate, ibandronate, risedronate, denosumab, and, zoledronic acid comes with various complications. The most prevalent adverse effects of these drugs are gastrointestinal, such as acid reflux, pain and esophagitis.87 Extended usage of bisphosphonates may raise the chances of rare but severe consequences, such as osteonecrosis of the jaw, significant decrease in bone metabolism and atypical fractures.89,103). It is vital to note that osteonecrosis of the jaw is more common in cancer patients undergoing bisphosphonate medication. However, the relatively limited number of documented cases has made it difficult to establish a definitive cause-and-effect relationship. Additional studies are required to completely comprehend the association and identify the risk factors for this serious condition.
Denosumab has several drawbacks including adverse effects such as eczema of the skin, flatulence, inflammation of the skin, and osteonecrosis of jaw. The long-term safety and effectiveness of denosumab remain uncertain. Risk of infections may increase because denosumab inhibits the immune system. Some patients may experience atypical femoral fractures. Its subcutaneous administration usually requires a visit to a healthcare provider, which can be inconvenient for patients, particularly those with limited mobility or access to healthcare facilities.104
SERMs can cause adverse reactions such as hot flashes, leg cramps, and a heightened risk of blood clotting. Investigation is underway to assess long-term safety and efficacy of SERMs in preventing osteoporosis. SERMs may not be as effective as bisphosphonates. Their use may be inappropriate for individuals with a history of blood clots or liver disease.105
Teriparatide is found to be allergic to several consumers. Individuals with allergies to teriparatide or any of its constituents should avoid taking it. Those with certain conditions which necessitates the use of teriparatide, should proceed with caution. Teriparatide's safety and efficacy are uncertain. Animal studies suggest a risk of osteosarcoma, but the relevance to humans is uncertain. Teriparatide should only be used for high fracture risk individuals who have not responded to previous osteoporosis medications.106
Calcitonin has several limitations, including a short half-life requiring frequent dosing, uncertain effectiveness in postmenopausal osteoporosis, potential for antibody development with long-term use, and its limited effectiveness, making it a non-preferred option for first-line treatment of hypercalcemia.107
8 Expected new drugs under investigation
Recently, there has been noteworthy success in the treatment of osteoporosis, as new drugs focus on promoting bone development while decreasing bone breakdown.
8.1 Romosozumab
Romosozumab represents a significant advancement in the management of osteoporosis as the first FDA-approved monoclonal antibody specifically designed to inhibit sclerostin.108 The glycoprotein sclerostin, which is primarily generated by osteocytes, the most common cells in bone tissue, is vital for controlling the process of bone remodeling. The formation of sclerostin is governed by the SOST gene, localized on chromosome 17q12-q21 in humans. Sclerostin functions as a negative regulator of the Wnt signalling pathway.109
In the physiological context, in order to sustain bone homeostasis, bone growth and resorption must be in a dynamic equilibrium. Central to the process of bone development is the Wnt signaling pathway, which is critical for the proliferation and differentiation of osteoblasts, the cells accountable for bone synthesis. Upon interaction of Wnt proteins to receptor complexes, including Low-Density Lipoprotein Receptor-Related Protein 5/6 (LRP5/6), a signaling cascade is initiated, leading to the stabilization and nuclear translocation of β-catenin. This translocation of β-catenin to the nucleus subsequently activates gene transcription that promotes osteoblast activity and bone formation.110 Additionally, increased amounts of β-catenin promote osteoprotegerin production, blocking RANKL from interacting with RANK and thus halting osteoclast stimulation and bone erosion. Therefore, this pathway enhances bone creation by activated osteoblasts and decreases bone breakdown by disrupting RANKL-to-RANK binding.110 Sclerostin by binding to LRP5/6, it inhibits Wnt protein interaction, thereby blocking the downstream signaling necessary for osteoblast activation and bone formation. This inhibitory mechanism of sclerostin is crucial for maintaining bone mass; however, excessive sclerostin activity can lead to an imbalance favoring bone resorption over formation, a condition observed in osteoporosis.109,111,112 Moreover, studies showed that LRP4, along with LRP5 and LRP6, interacts with sclerostin and is crucial in maintaining bone balance.113 Mutations in LRP4 that disrupt this binding result in altered bone growth.114
Romosozumab was developed to counteract the inhibitory effects of sclerostin. By neutralizing sclerostin, romosozumab effectively removes the inhibition on the Wnt signalling pathway, thereby enhancing bone development mediated by osteoblast and concurrently lowering bone resorption mediated by osteoclast. This dual-action mechanism makes romosozumab a unique therapeutic agent in osteoporosis treatment.108 The inhibition of sclerostin by romosozumab not only presents a novel approach for osteoporosis but also has broader implications for conditions related to the Wnt-β-catenin pathway, including metabolic disorders like obesity and diabetes, as well as certain malignancies. The role of sclerostin in these diverse physiological processes underscores its significance as a therapeutic target.115
Studies showed that people with very thick bones have a deficiency in sclerostin. Further insight into sclerostin's role in bone metabolism has been gained via the studies conducted on sclerosteosis and van Buchem disease which are rare genetic disorders that affect bone density and linked to the gene SOST, which codes for the sclerostin protein. Sclerosteosis, also known as osteopetrosis with syndactyly, is often seen in South African patients, while van Buchem illness, also known as familial cerebral hyperostosis, is more prevalent in the Netherlands. Sclerosteosis is associated with mutations that is responsible for a complete functional loss of the SOST gene. The lack of functional sclerostin in sclerosteosis leads to excessive bone growth and abnormally high bone density, particularly in the skull and long bones. On the other hand, van Buchem disease is also linked to the SOST gene, but it is characterized by a reduction in the expression of this gene rather than a complete loss of function. As a result, there is less inhibition of bone formation, leading to improved bone density, though the effects are generally milder compared to those seen in sclerosteosis.116–119
These observations are corroborated by animal studies where omission of the SOST gene or administering sclerostin-neutralizing antibodies produced similar increases in BMD, while elevated sclerostin level was correlated with attenuated bone density.112 The inhibition of sclerostin in the Wnt-β-catenin pathway is found to positively impact on bone density. Researchers have observed significant improvements in bone formation in postmenopausal osteoporosis models, specifically ovariectomized rats administered with sclerostin antibody, including increased levels of osteoblasts and mineralizing bone forming surfaces, along with decreased levels of osteoclast on bone resorption surfaces (Scl-Ab). These findings indicate that Scl-Ab therapy may promote bone growth and reduce bone resorption, advocating it as a successful treatment strategy for people with osteoporosis.120 Another study showed that Scl-Ab enhances osteoprogenitor differentiation to osteoblasts. On the other hand, parathyroid hormone (PTH) 1–34, a commonly used anabolic treatment for osteoporosis, not only stimulates the differentiation of osteoprogenitors into osteoblasts but also consistently increases the overall number of osteoprogenitor cells. This dual action of PTH 1–34 results in a more substantial rise in bone formation, as it both boosts the pool of precursor cells and enhances their maturation into active bone-forming cells.121 In cynomolgus monkeys, BMD and bone strength was increased with the treatment of Scl-Ab which was also comparable to rats. It was observed that bone resorption markers did not increase while, there was a notable rise in bone formation markers, suggesting that Scl-Ab affects bone formation differently than parathyroid hormone 1–34 (PTH1-34).122
Clinical trials of romosozumab have demonstrated significant improvements in BMD and bone strength, particularly in postmenopausal women with osteoporosis. Romosozumab ability to simultaneously enhance osteoblast activity and reduce osteoclast activity positions it as a potent therapeutic option.123–125 However, its use is associated with potential adverse effects, including arthralgia, headaches, and injection site reactions, as well as rare but serious complications like osteonecrosis of the jaw and atypical femoral fractures.126 Consequently, romosozumab is contraindicated in patients with hypocalcemia, a recent history of cardiovascular events, or known hypersensitivity to the drug.127,128 The FDA authorized rovosozumab in April 2019, marking a new era in osteoporosis treatment. The fabrication of sclerostin inhibitors like romosozumab continues to hold promise not only for osteoporosis but also for a variety of other conditions influenced by the Wnt-β-catenin pathway, reflecting the broader therapeutic potential of targeting sclerostin in clinical practice.
8.2 Cinacalcet
Bone loss associated with aging in men differs significantly from postmenopausal osteoporosis in women. In men, bone loss typically begins in their sixth decade of life (50s or 60s) and progresses more gradually than in women. This difference is largely due to hormone irregularities, poor nutrition and lifestyle factors. Common causes include poor calcium absorption, vitamin D insufficiency, and secondary hyperparathyroidism. Testosterone and estradiol levels decrease with age, impacting bone health. Estradiol is important for maintaining bone mass in both genders. Contrary to women, males lose trabecular and cortical bone mass in different manners. Excessive cortical bone remodeling and reduced bone formation are major factors in bone loss in older men. Anabolic treatments, which promote bone formation, may be more effective than antiresorptive agents in treating male osteoporosis.
Cinacalcet is a calcimimetic drug used to lower parathyroid hormone (PTH) levels. Parathyroid cells detect calcium levels in the extracellular matrix through a calcium-sensing receptor (CaR) on their surface, also termed as a G-protein coupled receptor or "extracellular calcium receptor." Certain molecules are referred to as "type I calcimimetics" because of their ability to mimic the effects of extracellular calcium (ecCa2+). Related compounds were designated as "type II calcimimetics" because they altered the structure of the calcium-sensing receptor (CaR) and specifically enhanced its sensitivity to ecCa2+. However, type II calcimimetics cannot function independently of ecCa2+ and do not fully replicate its effects. Therefore, labeling them as calcimimetics may be less precise, and they could be more accurately described as "positive allosteric modulators of CaR”. Research using site-directed mutagenesis suggests that the mechanism of action of type II calcimimetics may be linked to their interaction with the seventh transmembrane domain of the CaR. This interaction potentially alters the receptor's conformation and its response to extracellular calcium levels. On the other hand, calcilytics are compounds that inhibit the calcium-sensing receptor (CaR), leading to an augmented secretion of parathyroid hormone (PTH). Calcilytics effectively counteract the action of extracellular calcium and can be used to treat conditions characterized by excessive suppression of PTH.129
The calcium-sensing receptor (CaR) on the exterior of parathyroid cells plays a crucial role in regulating parathyroid hormone (PTH) release. When extracellular ionized calcium (ec[Ca2+]) levels increase, CaR activation leads to decreased PTH secretion and reduced bone turnover. CaR is a promising target for therapeutic interventions. Calcimimetics enhance CaR responsiveness to extracellular calcium (Ca2+), which lowers PTH levels and subsequently decreases blood calcium levels. They have been observed to lower PTH release in parathyroid cell cultures, animal models, and humans in a dose-dependent manner, and also lower calcium-phosphorus product levels in the bloodstream. Therefore, calcimimetics can serve as a novel treatment for secondary hyperparathyroidism and may assist in lowering the risk of osteoporosis, as secondary hyperparathyroidism can contribute to bone loss. Thus, calcimimetics may also be considered an indirect therapeutic agent for osteoporosis.130
A study started in July 2019, and expected to be completed by July 2025, is currently being conducted in California, USA. The research focuses on evaluating the efficacy of a combination therapy involving teriparatide (TPTD) and a calcimimetic agent. The research began with preclinical studies on mice to evaluate the efficacy of combining teriparatide (TPTD) and a calcimimetic agent. Preliminary results in mice indicated that TPTD stimulates anabolic effects through PTH receptors in osteoblast lineage cells.131 Additionally, animal studies have demonstrated that combining PTH1-34 with a calcimimetic agent has significant positive effects on bone. Both calcium-sensing receptors (CaRs) and parathyroid hormone receptors (PTH-Rs) play crucial roles in bone remodeling. Conditional knockout experiments in mice have shown that CaRs are involved in skeletal development and bone cell function. High levels of calcium activate CaRs, which are thought to initiate a bone-building pathway similar to the activation of PTH-R by PTH1-34. This CaR activation in bone cells can potentially enhance osteoblast (OB) activity while suppressing osteoclast (OC) function.132
8.3 Tiliroside
Tiliroside, a glycosidic flavonoid type, has been found to possess anti-inflammatory characteristics. It restricts the overproduction of nitric oxide (NO) in macrophage cells that are stimulated by lipopolysaccharide. It also reduced the expression of inducible nitrogen oxide synthase (iNOS) and COX-2 induced by lipopolysaccharide. Tiliroside also blocks the stimulation of Jun N-terminal kinase (JNK) and p38 proteins, which are components of the MAPK signaling pathway. Nevertheless, the phosphorylation of ERK 1/2 or the degradation of IkB-a protein remains unaffected by it. Tiliroside combats inflammation by reducing iNOS and COX-2 protein levels, while also inhibiting the MAPK, JNK and p38 signaling pathways.133 Studies reveal that in mice with ovariectomy-induced osteoporosis, it inhibits bone loss. Also, in laboratory studies, it prevents the production of bone-resorbing cells and the breakdown of bones prompted by RANKL. Tiliroside may be used for treating the osteoporosis by decreasing the activation and expression of signaling proteins regulated by RANKL, as well as by reducing the generation of ROS in cells involved in osteoclast formation. Moreover, tiliroside also obstructs the activation of MAPK and T-cell NF-κB pathways triggered by RANKL, and reduces the expression of genes associated with osteoclastogenesis.134,135
9 Expected new therapeutic targets for management of osteoporosis
Numerous potential targets for osteoporosis research are being explored for future treatment options. Some of these targets have been tested in animal studies, while others have shown promise in recent research involving specific medications and therapeutic approaches.
9.1 Wingless related integration site/beta catenin pathway
The Wingless related integration site/β-catenin (Wnt/β-catenin) signaling pathway is an essential biochemical mechanism that controls various biological activities like cell proliferation, differentiation, and gene expression. This process is essential for the development of osteoblasts by guiding pluripotent mesenchymal stem cells (MSCs) to differentiate into osteoblasts, thereby promoting their development into bone-forming cells. The Wnt/β-catenin pathway activates specific genes to initiate and sustain osteoblast formation while inhibiting the transformation and maturation of unspecialized mesenchymal stem cells (MSCs) into specialized chondrogenic and adipogenic cells. This process promotes osteoblast differentiation, which is essential for maintaining bone health. Moreover, WNT/ᵦ catenin signaling helps Osterix1-expressing cell transform into active osteoblast, a pivotal factor in osteoblast differentiation and bone formation. This signaling pathway also prevents the death of mature osteoblasts by activating both ß-catenin-dependent and independent pathways, prolonging their survival and allowing for ongoing bone growth and maintenance.136 Genetic research has linked mutations in Wnt signaling pathways to variations in bone density. Studies on patients with unusually dense or weak bones have identified mutations in the SOST gene and the LRP5 gene, which transcribe and translate into sclerostin, an inhibitor of Wnt signaling. These mutations are responsible for the observed differences in bone density.137 The absence of sclerostin in bone leads to conditions like Sclerosteosis and Van Buchem disease, while mutations that decrease LRP5 activity result in osteoporosis-pseudoglioma syndrome. Multiple Wnt proteins, comprising Wnt1, Wnt3a, Wnt4, Wnt5, Wnt5a, Wnt7a, Wnt10b, and Wnt14, are essential for bone development and maintenance. For example, Wnt10b is particularly significant in stimulating bone growth and altering adult bone structure.138 Additionally, R-spondin proteins in mammals enhance Wnt/β-catenin signaling, playing a chief role in regulating bone growth and maintenance. Disruptions in the Wnt/β-catenin pathway, such as alterations in the Wnt1 gene, have been linked to early-onset osteoporosis and severe brittle bone disease, underscoring the vital part in Wnt signaling in maintaining bone health.139 Individuals with a single SOST mutation often have normal to high bone mineral density (BMD) levels, without exhibiting the severe traits seen in those with mutations in both alleles. This suggests that a modest reduction in sclerostin levels, augment the expression of the SOST gene, thus enhance Wnt signaling and promote bone formation without causing adverse effects.109 Evidence indicates that PTH can decrease sclerostin synthesis by osteocytes. However, the impact of Romosozumab, an antibody targeting sclerostin, on bone turnover markers has shown a speedy, significant but temporary rise in bone formation and less intense yet ongoing decrease in bone resorption. Denosumab on other hand, a neutralizing antibody targeting RANKL, has proven effective in reducing bone loss in osteoporosis.118,119 Further research into the Wnt/β-catenin pathway holds promise for developing treatments to enhance bone mass and treat osteoporosis by preventing excessive bone resorption and promoting bone formation.
9.2 Fibroblast activation protein
Fibroblast activation protein (FAP) is a serine protease enzyme that specifically targets and degrades proteins, including α2-antiplasmin, type I collagen, and fibroblast growth factor 21 (FGF21). Although initially identified in cancer biology, FAP is also engaged in a number of biochemical processes such as tissue remodeling and inflammation.140 Significant expression of FAP is observed in bone marrow stromal cells, which differentiate into osteoblasts. In this context, FAP may act as a modulator of osteogenesis, potentially inhibiting osteoblast function and contributing to conditions such as osteoporosis. Additionally, FAP affects the extracellular matrix, which in turn affects bone health and cellular environment. FAP also plays a role in the breakdown of key structural components like type I collagen, impacting tissue integrity and bone strength.141 Additional studies are needed to completely understand its impact as well as underlying mechanics.
Recently conducted study has shown therapeutic potential of targeting FAP to treat osteoporosis. Treating with osteoclastin, a natural inhibitor of FAP in joint cartilage, improves bone density and reduces fracture risk.142,143 Genetic removal or pharmacologically blocking FAP in mice led to significant improvements in bone density and structure, suggesting that FAP inhibitors could mitigate bone loss and enhance bone formation.144 These findings propose that preserving or enhancing Osteolectin levels may offer a promising strategy to counteract osteoporosis by promoting bone growth and lowering the likelihood of fracture.145
9.3 Nucleotide-binding oligomerization domain-like-receptor family pyrin domain-containing 3
The nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome is a cluster of proteins within cells that helps to regulate the generation and discharge of inflammatory molecules like interleukin (IL)-18 and IL-1β. This process can lead to inflammation and pyroptosis (cell death via inflammation). Signal 1 (priming) and signal 2 (activation) are the two essential signals that the NLRP3 inflammasome needs to activate. Priming is an initial step in which the NF-κB pathway being triggered via inflammatory signals, resulting in the upregulation of NLRP3 expression and the pro-forms of IL-18 and IL-1β. The NF-κB pathway is stimulated by factors like aging or low estrogen levels. These conditions can lead to chronic inflammation, enhancing the body's inflammatory response by producing more NLRP3 and other inflammatory proteins. Activation represented by signal 2 is the second signal activates the inflammasome after priming. This can be triggered by various cellular stressors such as changes in potassium levels, generation of reactive oxygen species (ROS), or injury to cell structures like lysosomes. Upon receiving these signals, the NLRP3 inflammasome assembles, with NIMA (Never in mitosis A)-related kinase 7 (NEK7) playing a crucial role in this process. NEK7 interacts with NLRP3, promoting the migration of ASC (apoptosis-associated speck-like protein containing a CARD) and pro-caspase-1, leading to the building of the active complexes of inflammasome. These complexes further facilitate the conversion of procaspase-1 to caspase-1, which then activate IL-18 as well as IL-1β. This activated form of IL-18 and IL-1β are released to cause inflammation.146,147
Excessive stimulation of the NLRP3 inflammasome, particularly in the context of aging or estrogen deficiency, accelerates bone degradation through two main mechanisms. First, it stimulates osteoclastogenesis, which is the formation of osteoclasts (cells that break down bone tissue). This elevated activity of osteoclasts results in greater bone resorption and loss. Second, the NLRP3 inflammasome inhibits osteoblastogenesis, the process responsible for the formation of osteoblasts that build new bone. This suppression of osteoblast function reduces bone formation. Together, these effects disrupt the equilibrium between the formation and resorption of bone, contributing to the development of osteoporosis and an elevated risk of fractures. Moreover, overactivation of the NLRP3 inflammasome may result in pyroptosis that damages osteoblasts, further exacerbating bone loss. The presence of elevated levels of caspase-1 and Gasdermin-D, which are involved in pyroptosis, underscores the link between inflammasome activation and osteoblast dysfunction.148 Research indicates that genes associated to the NLRP3 pathway, such as CASP1, CARD8, NLRP3, IL-18, and IL-1β, are linked to osteoporosis severity, suggesting their role in bone metabolism and dysregulation.149 In summary, the inflammasome NLRP3 is a significant component in the pathogenesis of osteoporosis, particularly in the context of chronic inflammation associated with aging or estrogen deficiency. In addition to encouragement in bone resorption and inhibition of bone formation, its activation also contributes to osteoblast damage through pyroptosis, thus worsening osteoporosis.148
9.4 Cuproptosis
Copper (Cu) is a vital micronutrient that plays a critical role of cofactor that catalysis a broad variety of biological activities. These functions include biocompound synthesis, mitochondrial bioenergetics and free radical scavenging.150,151 Cu also functions as a cofactor for bone remodeling enzymes. Thus executes a crucial function in bone health.152 One of the enzymes is lysyl oxidase, that is critical for the cross-linkage of elastin and collagen in bone and connective tissues, highlighting Cu importance in maintaining bone integrity and lowering the likelihood of osteoporosis.152 Consequently, in order to maintain the usual biological activities, it is essential to maintain an acceptable amount of Cu concentration throughout the system. Conversely, if the Cu content is higher than the acceptable level, it becomes extremely toxic and ultimately results in the death of cells. Consequently, the metabolism of Cu inside the cell is extensively controlled. Disruption in the metabolism of Cu within the cell leads to Cu induced toxicity or specific type of Cu induced cell death referred to as cuproptosis.153 The precise pathophysiology underneath cuproptosis is not well understood. A variety of process, including mitochondrial insufficiency, endoplasmic reticulum stress, oxidative stress, as well as disruption in the metal ion homeostasis. Accumulated Cu interacts to lipoylated enzymes in the tricarboxylic acid cycle (TCA). This interaction results two subsequent events. Firstly, a rise in the newly lipoylated proteins which leads to protein aggregation. Thus, resulted in accumulation and aggregation of damaged or misfolded proteins i.e., proteotoxic stress. Secondly, a decrease in iron-sulphur cluster proteins. These events combinedly disrupt protein balance, eventually resulting in programmed cell death.154–156
Cuproptosis has been linked to a number of illnesses including neurodegenerative diseases and cancer.157–160 In addition to cancer and neurodegenerative disorders, cuproptosis also significant involve in pathogenesis of osteoporosis158,159. Osteoporosis is caused by irregularities in the microenvironment of bone marrow and cellular homeostasis irregularities. Cells comprising bone marrow stromal cells (BMSCs), osteocytes, osteoblasts, osteoclasts, chondrocytes, macrophages, adipocytes and endothelial cells have cuproptosis-related metabolic pathways.143,161 An investigation conducted on rodents displayed that augmented level of Cu inhibits differentiation of bone marrow mesenchymal stem cells (MSCs) into osteoblasts through downregulation of Runx2 gene and stabilization of hypoxia-inducible factor (HIF)-1 α protein.162
Osteoclasts decrease significantly with increase in Cu concentration.163,164 Furthermore, Cu overload can additionally generate blood vessels in fibrous tissue while retard bone regeneration due to reduce bone-marrow tissue.165 Excessive Cu produces reactive oxygen species (ROS) and free radicals that damage lipids and affect bone metabolism, which may explain this finding.166,167 ROS encourage cells associated with bone formation to harvest RANKL, macrophages colony stimulating factor (M-CSF) and osteoprotegerin, which recognize osteoclasts and its precursor cells and send signals for bone resorption.168 One research found that US adults' dietary and total Cu consumption increased BMD and decreased osteoporosis risk.169 In another study conducted on rodents it was found during the 76–198-day age range, Cu content in bone decreased, whereas within the 200–1000-day age range, Cu built by 61 %. Cu affects collagen and BMD. Cu inversely linked with bone calcium, collagen, and density. Therefore, excess Cu was the main cause of bone size and density loss.170 There are 10 cuproptosis-related genes (CRGs) was linked to Cu ion-induced cell death. These gene include cyclin-dependent kinase inhibitor 2A (CDKN2A), dihydrolipoamide S-acetyltransferase (DLAT), dihydrolipoamide dehydrogenase (DLD), glutaminase (GLS), metal regulatory transcription factor 1 (MTF1), pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1), and pyruvate dehydrogenase E1 subunit beta (PDHB) have been shown to affect the biology of cartilage and bone by controlling the activities of osteoclasts, osteoblasts, and chondrocytes.159,171 These findings highlight how crucial it is to control Cu levels in order to maintain optimal bone function and the potential hazards of cuproptosis on bone health. Thus, cuproptosis play a crucial target function in managing osteoporosis.
9.5 Purino receptor 7
The P2X7 receptor (P2X7R), a purinergic receptor, is essential for bone homeostasis because it regulates bone production and resorption. Additionally, the P2X7R also involved in the inflammation and the Wnt/β-catenin signaling pathway, all of which are crucial for bone health. P2X7R serves as a ligand-gated ion channel in the extensive communication system of osteocytes, osteoclasts, and osteoblasts during bone remodeling and repair.172 Upon P2X7R stimulation, intracellular ATP is released, which then act on the same receptor to promote the differentiation of MSCs in bone tissue from their undifferentiated state.173 The ability of P2X7R to elicit ATP release and consequently activate downstream signaling pathways, such as MAPK, and the expression of c-Jun and c-Fos mRNAs, is well documented.174 P2X7R also plays a role in triggering signaling messengers like NF-kB, which are key regulators of gene expression related to inflammation. NF-kB activation, induced by P2X7R, has been observed in microglia, osteoclasts, and osteoblasts, linking P2X7R to inflammatory responses.175 In osteocytes, P2X7R detects mechanical stress within the bone, triggering signaling pathways that determine whether bone formation or resorption should occur, which is vital for adapting bone structure to mechanical demands. In osteoclasts, P2X7R facilitates the release of pro-inflammatory cytokines and ATP, promoting bone resorption, a mechanics crucial for bone turnover and the removal of old or damaged bone. Conversely, in osteoblasts, P2X7R supports bone deposition and mineralization, crucial for repairing and strengthening bone tissue. The receptor's dual role in both bone breakdown and healing underscores its importance in maintaining bone balance. P2X7R is essential for the restoration and remodeling of microcracks in bone, reinforcing the healing process and ensuring structural integrity.173,176 A study showed that mice knockout for the P2X7 receptor have a distinct skeletal phenotype characterized by insufficient periosteal bone production and increased trabecular bone resorption.177 In other study conducted on mouse model of inflammation-mediated osteoporosis, it was concluded that the P2X7 receptor is involved in inflammatory bone loss, since the wild type mice lost bone strength, BMD, and trabecular microarchitecture whereas the P2X7 receptor knockout mice did not.178 Thus, genetic variants of the P2X7 gene is linked to heightened susceptibility to osteoporosis and a greater likelihood of fractures, indicating the need for finely tuned receptor activity. All of these suggests that P2X7R might be a useful therapeutic target for the management or prevention the progression of osteoporosis.179 Consequently, P2X7R inhibitors are currently being researched as potential therapies for osteoporosis, aiming to lower excessive bone resorption and enhances bone formation. Blocking P2X7R can potentially mitigate the bone loss and enhance bone density in osteoporosis. However, the effectiveness of P2X7R inhibitors for treating osteoporosis is still under investigation and requires further research.172
9.6 Tumor necrosis factor receptor associated factor 3
Tumor necrosis factor receptor-associated factor 3 (TRAF3) is a critical adaptor protein which is involved as a key player in regulating the growth and activity of osteoclasts and osteoblasts. TRAF3 hinders osteoclast formation by preventing the conversion of p100 to p52, a crucial step in the non-canonical NF-κB signaling pathway, thereby limiting osteoclast differentiation. During osteoclast maturation, the levels of TRAF3 protein correlate with those of p100 protein, and higher TRAF3 levels are associated with reduced osteoclast development. This complex regulatory process underscores the importance of TRAF3 in regulating the differentiation of bone cells, making it an emerging therapeutic target for treating bone disorders.180 Prior studies did not thoroughly examine the role of TRAF3 in mesenchymal cells, which are crucial for bone development as they give rise to osteoblasts and chondroblasts. Recent research addressed this gap by employing a conditional knockout approach, where TRAF3 was specifically removed from mesenchymal precursor cells through the breeding of TRAF3fl/fl mice with Prx1cre mice. These conditional knockout mice demonstrated normal skeletal development and bone density till they reached three months of age. However, by nine months, they developed early onset osteoporosis, characterized by fragile bones more prone to fractures. This osteoporosis resulted from increased bone resorption coupled with decreased bone formation, highlighting the critical role of TRAF3 in maintaining bone homeostasis. These data indicate that TRAF3 may be a viable target for therapeutic interventions aimed at preventing or treating osteoporosis by modulating resorption and formation of bone.134,135
The degradation of TRAF3 is crucial for activating signaling pathways that promote osteoclast differentiation, a key process in bone remodeling and homeostasis. Ubiquitination, or the binding of ubiquitin molecules to target proteins, marks them for breakdown by the proteasome. In this context, the TRAF3/TRAF2/cIAP complex mediates the ubiquitination of NIK (NF-κB-inducing kinase), leading to its breakdown by the proteasome. The degradation of NIK inhibits the activation of IKKα (IκB kinase α) and prevents the processing of p100 into p52, a key step in the non-canonical NF-κB signaling pathway. This inhibition blocks the translocation of p52/RelB dimers to the nucleus, which is essential for the transcriptional activation required for osteoclast development. Therefore, regulated TRAF3 degradation is critical for controlling osteoclastogenesis, which in turn maintains bone health and integrity. Understanding this mechanism provides insight into potential therapeutic strategies for bone disorders associated with impaired osteoclast differentiation.181 When RANKL binds to its receptor (RANK) initiates a cascade of events resulting in the breakdown of TRAF3 via ubiquitination and autophagolysosomal degradation. This breakdown enables the build-up of NIK, which triggers IKKα, resulting in the phosphorylation of p100 and its conversion to p52, ultimately stimulating the creation of osteoclasts. Increased cytokines production, driven by various pathological processes and aging process, prompts mesenchymal progenitor cells, osteoblastic cells, and B and T lymphocytes to increase their production of RANKL. The attachment of RANKL to its receptor (RANK) present on osteoclast precursors leads in TRAF3 ubiquitination and lysosomal degradation, letting NIK to convert p100 to p52. This conversion supports the creation of p52/RelB heterodimers, enhancing bone remodeling. Chloroquine and similar inhibitors of lysosomal degradation can prevent TRAF3 degradation, resulting in decreased NIK degradation and hindering osteoclast formation. The presence of TRAF3 in mesenchymal progenitor cells promotes their differentiation into osteoblasts while reducing RANKL production, thus supporting bone formation and preventing bone resorption.181 These outcomes illuminate the previously undiscovered part of TRAF3 in preventing age-associated bone loss. While the exact mechanisms through which TRAF3 mediates this effect are still being studied, the results suggest that maintaining TRAF3 levels could be a promising strategy for enhancing bone mass in various bone conditions. This approach might work by inhibiting excessive bone breakdown and supporting bone growth, which could ultimately improve bone strength and overall skeletal health. Further research into TRAF3's mechanisms could provide valuable insights for designing tailored medicines to address age-associated bone loss and other bone disorders.
9.7 Krüppel-like factor transcription factor
The family of Krüppel-like factor (KLF) transcription factors is crucial for regulating gene expression by binding to specific DNA sequences. Named after the German word "Krüppel," meaning "cripple," KLFs were first identified in fruit flies due to their role in embryonic development. These variables are engaged in a range of biological processes, including cell differentiation, proliferation, and apoptosis, across different species, highlighting their fundamental importance in development and disease. These elements regulate gene function by stimulating or inhibiting the transcription of DNA through their attachment to KLF binding sites located in the control areas of specific genes. The disruption of KLFs has been associated with several illnesses, such as cancer, cardiovascular diseases, and metabolic disorders. Understanding KLFs is essential for uncovering the mechanisms of gene expression regulation and identifying possible therapeutic targets for bone disorders.182
In osteoporosis research, KLFs are recognized as chief regulators of osteoblast differentiation, significantly influencing the progression of osteoporosis.182 KLF2 and KLF10 act as advantageous stimulators that enhance bone metabolism and differentiation. Elevated KLF2 levels have been linked to the increased formation of bone nodules and elevated levels of osteoblast differentiation markers. These markers comprise alkaline phosphatase, bone sialoprotein, RUNX2 (Runt-related transcription factor 2), OSX (osterix), and osteocalcin. The presence of KLF2 promotes osteoblast differentiation and activity, contributing to enhanced bone formation. KLF2 boosts osteogenic differentiation by upregulating osteoblast-specific genes through its interaction with RUNX2.183 Similarly, KLF10 enhances Runx2 gene expression, potentially through its effects on the ubiquitin/proteasome pathway or by modulating cytokines like bone morphogenetic protein 2 (BMP2) and transforming growth factor-β1 (TGF-β1). By influencing these pathways, KLF10 supports development of osteoblast and mineralization of bone.184 On the other side, KLF3 and KLF15 act as inhibitors of bone formation, which can exacerbate osteoporosis. KLF3 impairs bone formation by inhibiting JunB gene activity, a key factor in osteoblast differentiation and function. This inhibition can be counteracted by a mutated Reg1cp lncRNA or by the compound Ophiopogonin D, both of which boost JunB levels and help mitigate the effects of osteoporosis. By restoring JunB expression, these interventions can alleviate some of the negative impacts of KLF3 on bone health.185 Increased levels of KLF15 reduce bone formation indicators and exacerbate the inhibition of bone growth in osteoporosis, while restricting its activity with substances such as tanshinol, enhances the formation of new bone tissues.186 Together, KLF3 and KLF15 are crucial factors in osteoporosis development, providing potential targets for specific drug treatments.
9.8 Toll like receptor 4
Toll-like receptors (TLRs), an essential component of the innate immune system, operating as pattern recognition receptors that identifies pathogen-associated molecular patterns (PAMPs) on numerous pathogens. Mainly found on immune cells like dendritic cells, macrophages, and B cells. In addition to detect PAMPs, TLRs trigger signaling cascades that activate immune responses. These responses involve the generation of pro-inflammatory cytokines, chemokines, and type I interferons, which are crucial for defending the host against infections. Structurally, TLRs consist of transmembrane proteins with an external ligand-binding domain, a transmembrane segment, and an internal Toll/interleukin-1 receptor (TIR) region. Human TLRs comprise 10 different types of receptors (TLR1-10), each capable of recognizing specific PAMP. For instance, TLR4 recognize lipopolysaccharide from gram-negative bacteria, while TLR3 recognized viral double-stranded RNA. Upon ligand binding, TLRs activate signaling pathways like the MyD88-dependent and TRIF-dependent pathways, resulting in the stimulation of transcription factors such as NF-κB and IRF3 that control the expression of genes involved in immunity.187 Dysregulation of TLR signaling in medical practice is associated with autoimmune disorders, inflammatory diseases, and cancer, indicating that targeting TLRs for therapeutic interventions could help regulate immune responses in these conditions.188
TLR4, a central receptor in immune reactions, is becoming increasingly essential in the development of osteoporosis due to its complex role in different proteins and signaling pathways. Bone remodeling, which regulates bone production and resorption, requires TLR4. An E3 ubiquitin ligase, Cullin 4A, regulates genes including ZEB1 and miR-340-5p, which activate TLR4 and impact bone strength. Additionally, TLR4 interacts with regulatory molecules such as miR-137, miR-630, Circ_0134944, and KDM4A, which modulate its expression and influence the development of osteoporosis. Furthermore, TLR4 impairs osteoblast function by suppressing key genes like RUNX2, which is vital for differentiation of osteoblast and formation of bone. It also initiates the S100B/ERK signaling pathway, which adversely affects osteoblast activity. Furthermore, TLR4 stimulates the discharge of proinflammatory cytokines via the MyD88/NF-κB signaling pathway, including TNF-α, IL-1, and IL-6. These cytokines contribute to chronic inflammation and augment bone resorption, resulting in declining bone health.189,190 Osteoblasts have close interactions with immune cells in the bone environment, playing a vital role in responding to inflammatory stimuli and regulating bone balance. Immune cells affect osteoblast activity by releasing cytokines and signaling molecules, and in turn, osteoblasts impact immune cell function, establishing a dynamic relationship between the immunological and skeletal systems. Understanding these mechanics underscores the potential of targeting TLR4 for therapeutic interventions to manage or prevent osteoporosis. Thus, TLR4 inhibitors or modulators may customize the immune response to benefit bone health and reduce inflammation-induced bone loss in osteoporosis.191
9.9 Yes-associated protein/transcriptional coactivator with pdz-binding motif
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are essential downstream targets of the Hippo signalling pathway in mammals. They regulate gene expression and cellular responses to various internal signals, significantly contributing to the growth of cells, cell death, and cell specialization, which are crucial for tissue development and maintenance. YAP and TAZ interact with other Hippo pathway components to regulate genes that control cell proliferation and survival. Initially identified as tumour suppressors in Drosophila melanogaster, their role has expanded to include regulation of stem cell properties. Disruption of the Hippo pathway can lead to abnormal cell proliferation and is associated with various diseases, including cancer, as well as age-related disorders such as neurodegenerative diseases, cardiovascular issues, fibrosis, and tissue degeneration.192 In mammals, the Hippo signalling pathway is a series of protein kinases that regulate cell growth and organ size. The pathway involves Macrophage Stimulating 1/2 (MST1/2) kinases, which phosphorylate as well as stimulate LATS1/2 (Large Tumor Suppressor 1/2), the mammalian counterparts of Drosophila Hpo (Hippo) and Wts (Warts), respectively. LATS1/2 are further activated by Salvador homolog 1 (SAV1) and are supported by Monopolar Spindle 1 (MOB1). When phosphorylated by MST1/2, LATS1/2 achieve their maximum efficiency, leading to the phosphorylation and inhibition of YAP and TAZ. This phosphorylation blocks YAP and TAZ from translocating to the nucleus and promotes their degradation. Upon dephosphorylation, YAP and TAZ can enter the nucleus, where they function as transcriptional coactivators. They interact with DNA-binding transcription factors, primarily from the TEAD (TEA Domain) family, to regulate genes involved in cell proliferation and apoptosis. Beyond TEAD, YAP and TAZ also interact with various other transcription factors, broadening their regulatory influence over genes that control cell growth, differentiation, and tissue homeostasis.193
YAP and TAZ play crucial part in osteoporosis by intricately participating in cell differentiation, particularly in osteogenesis. These proteins significantly influence tissue-specific stem cell development, affecting the transition from growth to specialization, which is heavily influenced by their subcellular localization. In MSCs, which can differentiate into osteoblasts, chondrocytes, myocytes, and adipocytes, YAP and TAZ interact with various proteins and signalling pathways to regulate their activity. YAP and TAZ guide MSC differentiation toward the osteogenic lineage by interacting with transcription factors such as Runx2 and TEAD. The suppression or absence of YAP and TAZ has been linked to enhanced adipogenic differentiation and decreased osteogenic differentiation, indicating their critical role in maintaining the equilibrium between adipocyte differentiation and osteoblast in bone MSCs. Studies have demonstrated that TAZ augments differentiation of osteoblast and consequently, formation of bone in living organisms, resulting to an enhanced bone mineral apposition rate and a higher proportion of osteoblasts in TAZ-overexpressing mice. Conversely, TAZ knockout studies have shown increased osteoclast development and decreased bone density, underscoring its importance in regulating osteoclast maturation and bone resorption. Similarly, YAP promotes osteoblast proliferation and maturation, which are crucial for bone maintenance and growth. Overall, YAP and TAZ are pivotal in osteogenic and myogenic differentiation, as well as stem cell proliferation. Their functions are complex and context-dependent, influenced by interactions with various regulatory transcription factors and signalling pathways.194 Targeting YAP and TAZ holds significant promise for mitigating age-related bone and muscle tissues and improving the quality of life for the elderly.
9.10 Sirtuin 3
Sirtuin 3 (SIRT3), is an enzyme within the sirtuin family of NAD+ -dependent deacetylases, which plays a crucial role in regulating mitochondrial functions, metabolism, gene expression, and genomic integrity. SIRT3 is primarily localized in the mitochondria, where its deacetylates various proteins implicated in energy production, oxidative stress response, and metabolic processes. Its activity is essential for maintaining mitochondrial health and function, as well as for influencing overall cellular metabolism and longevity. SIRT3's role extends to conditions associated with age like osteoporosis, Parkinson's disease, Alzheimer's disease, and cardiovascular disorders. This underscores its significance in regulating cellular activities and influencing disease progression.195 Osteoporosis, characterized by bone loss, is closely connected to increased oxidative stress in osteoblasts. Some research studies demonstrated that nicotine exposure induces oxidative stress in mitochondria and damages mitochondrial DNA in osteoblasts, leading to osteoporosis. Nicotine lowers SIRT3 levels, decreasing the deacetylation of SOD2, a crucial enzyme in fighting oxidative stress in osteoblasts. The absence of SIRT3 disrupts mitochondrial biogenesis and its dynamics and via the PGC-1α/SOD2 pathway, impairing osteogenesis, the formation of new bone tissue. Both in vivo and in vitro studies confirm the critical role of SIRT3 in enhancing ATP production, promoting mitochondrial biogenesis and facilitating the development of bone-forming cells by deacetylating SOD2.196 ROS plays a significant part in cellular signaling, particularly in influencing osteoclast differentiation and activation caused by RANKL. Researchers found that reduced SIRT3 levels increased osteoclast production, contributing to bone loss in young female mice, understanding SIRT3's importance in bone health regulation. SIRT3 deacetylates lysine 68 on SOD2, lowering intracellular ROS levels and preventing osteoclast differentiation, thereby protecting bone mass and strength. Additionally, SIRT3 influences differentiation of osteoclast via AMPK-PGC-1β pathway, highlighting its potential as a therapeutic target for bone disorders.196
SIRT3 is also implicated in radiation-induced osteoporosis, hormone-related bone loss, and ageing. Ionizing radiation increases the levels and activity of SIRT3 in osteoclasts, promoting their differentiation and leading to eventual bone loss. Moreover, titanium negatively impacts the osteoclast function, and inhibiting SIRT3 in a mouse model prevented bone resorption and osteoclast formation induced by titanium particles through ERK and JNK signaling pathways. This suggests that SIRT3 modulates bone resorption to mitigate titanium-induced cell damage.197 The influence of SIRT3 on remodeling of bones may vary with age and gender, necessitating personalized therapeutic approaches. Increasing SIRT3 expression in youth could enhance bone formation, while reducing SIRT3 levels in old age might prevent bone loss and alleviate osteoporosis. Further animal studies and clinical trials are essential to confirm the effectiveness and safety of these approaches.
10 Conclusion
In conclusion, the field of osteoporosis research is rapidly progressing with the discovery of new medications, combination therapy, and the identification of novel targets focused on increasing bone formation and minimizing microstructural breakdown. New medications for osteoporosis include romosozumab, tiliroside and cinacalcet. Romosozumab, a monoclonal antibody inhibits sclerostin which further promote Wnt/ᵦ pathway and have shown efficacy in managing osteoporosis by promoting bone formation. Tiliroside, glycoside flavonoid which act as an anti-inflammatory agent which has an ability to inhibit overproduction of NO and reduce inflammatory markers like iNOS and COXII. Moreover, it can also block the specific signaling pathways like MAPK JNK P38 and highlights its multifaceted approach to prevent bone resorption followed by bone loss. A combination of teriparatide (TPTD) and cinacalcet (calcimimetic drug), can offer a unique approach to manage osteoporosis by modulating calcium levels as well as parathyroid function. Potential novel targets for preventing bone loss and osteoporosis which are explored in current article include Wnt/β-catenin pathway, FAP, NLRP3 inflammasome, cuproptosis, P2X7 receptor, TRAF3, Krüppel-like factor, TLR4, YAP/TAZ and Sirtuin 3. Extensive research has elucidated the pivotal part in Wnt/ᵦ catenin pathway in the management of osteoporosis by promoting the osteoblast differentiation and preventing the conversion of mesenchymal stem cells into adipogenic and chondrogenic cells. FAP inhibits bone formation by targeting and denaturing specific proteins like type I collagen and FGF21; so here osteolectin, act as a natural FAP inhibitor, has shown promise in enhancing bone health and reducing osteoarthritis progression. Stimulation of NLRP3 inflammasome can facilitate the production of inflammatory cytokines and pyroptosis, which may result in loss of bone and progression of osteoporosis. Factors like aging and estrogen deficiency can trigger NLRP3 activation, so targeting NLRP3 inflammasome pathways may be a promising way to develop interventions to manage inflammation-induced bone loss. Cu deficiency compromises energy metabolism, collagen formation, and antioxidant enzyme performance. These changes may weaken bones and increase fracture risk by affecting bone density and microstructure. Cu plays a critical role in regulating cell viability. However, its effects being highly dose-dependent. While essential at low levels, excessive Cu can cause toxicity and lead to a type of cell death known as cuproptosis. This delicate balance of Cu levels is crucial for maintaining optimal bone health, as Cu is involved in collagen formation and bone metabolism. Understanding the intricate relationship between Cu levels and cell viability offers a novel opportunity to explore new therapeutic targets to prevent cuproptosis, ultimately promoting better bone health. P2X7R is involved in purinergic signalling, inflammation, and the Wnt/β-catenin pathway. P2X7R is also very crucial for healthy bones. Inhibiting P2X7R could be a possible approach towards managing osteoporosis. TRAF3 limits osteoclast formation, which helps prevent bone loss. Since RANKL-RANK binding degrades TRAF3, preserving its levels could promote increased bone mass. KLF Transcription Factors or KLF proteins regulate osteoblast differentiation. KLF2 and KLF10 promote bone growth. KLF3 and KLF15 inhibit bone formation. Modulating these factors could enhance bone health. Dysregulation of TLR4 signalling is linked to autoimmune and inflammatory diseases. Inhibiting or modulating TLR4 could offer new therapeutic options. YAP/TAZ are key regulators of osteoblast differentiation, acting downstream in the Hippo pathway. Targeting these molecules could enhance bone formation. SIRT3 protects osteoblasts from oxidative stress and cytotoxicity, supporting bone health and balance.
Ethical statement
No human and animal study were conducted. Not applicable.
Funding statement
Bhagawati Saxena was the recipient of a Minor research project grant from Nirma University, Ahmedabad, Gujarat (Grant no: NU/DRI/MinResPrj/IP/2023–24, Date:01/03/23, UID: IP/2023-24/64).
Guardian/patient's consent
No Human study was conducted. Therefore, guardian/patient's consent is not applicable.
CRediT authorship contribution statement
Dhruvee Patel: Data curation, Writing – original draft. Bhagawati Saxena: Conceptualization, Methodology, Resources, Writing – review & editing, Supervision, Project administration, Funding acquisition.
References
- An overview of the management of osteoporosis in the aging female population. Women's Health. 2023;19
- [Google Scholar]
- An overview and management of osteoporosis. European Journal of Rheumatology. 2017;4(1):46-56.
- [Google Scholar]
- Current status of the diagnosis and management of osteoporosis. Int J Mol Sci. 2022;23(16)
- [Google Scholar]
- The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-2102.
- [Google Scholar]
- Animal model for glucocorticoid induced osteoporosis: a systematic review from 2011 to 2021. Int J Mol Sci. 2022;23(1)
- [Google Scholar]
- Epilepsy, antiepileptic drugs and bone health. Ann Indian Acad Neurol. 2006;9(2):90.
- [Google Scholar]
- FGF and ROR2 receptor tyrosine kinase signaling in human skeletal development. Curr Top Dev Biol. 2011;97:179-206.
- [Google Scholar]
- Endochondral ossification: recapitulating bone development for bone defect repair. Developmental Biology and Musculoskeletal Tissue Engineering: Principles and Applications 2018:125-148.
- [Google Scholar]
- Chemotaxis of human osteoblasts. Effects of osteotropic growth factors. APMIS : Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 1995;103(2):140-146.
- [Google Scholar]
- Osteoporosis: pathophysiology and therapeutic options. EXCLI Journal. 2020;19:1017-1037.
- [Google Scholar]
- An overview of glucocorticoid-induced osteoporosis. J Clin Rheumatol. 2022;5(5 suppl L)
- [Google Scholar]
- Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci. 2022;23(3)
- [Google Scholar]
- Risk of vertebral osteoporosis in post-menopausal women with alterations of the mandible. Dentomaxillofacial Radiol. 2007;36(3):143-148.
- [Google Scholar]
- The role of parathyroid hormone in alveolar bone resorption on postmenopausal women. Open Dent J. 2020;14(1):82-87.
- [Google Scholar]
- Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319-1328.
- [Google Scholar]
- Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev. 2018;39(5):519-548.
- [Google Scholar]
- Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Publ Health. 2019;16(9):1571.
- [Google Scholar]
- Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone. 2014;64:246-253.
- [Google Scholar]
- Possible involvement of pregnane X receptor–enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005;115(1):177-186.
- [Google Scholar]
- Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc. 2012;60(9):1761-1767.
- [Google Scholar]
- Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009;69(1):73-82.
- [Google Scholar]
- A concise review of testosterone and bone health. Clin Interv Aging. 2016;11:1317-1324.
- [Google Scholar]
- Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int. 2011;88(6):476-484.
- [Google Scholar]
- Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167(12):1246.
- [Google Scholar]
- Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res. 2006;21(1):163-170.
- [Google Scholar]
- Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover. J Intern Med. 2005;257(2):176-184.
- [Google Scholar]
- Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131-R151.
- [Google Scholar]
- Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid. 2002;12(5):411-419.
- [Google Scholar]
- Chronic kidney disease and osteoporosis: evaluation and management. BoneKEy Rep. 2014;3
- [Google Scholar]
- Diabetes mellitus and risk of low-energy fracture: a meta-analysis. Aging Clin Exp Res. 2020;32(11):2173-2186.
- [Google Scholar]
- Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using the health improvement network (thin) Diabetes Care. 2015;38(10):1913-1920.
- [Google Scholar]
- Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes. Bone. 2013;57(1):36-40.
- [Google Scholar]
- Effects of weight and body mass index on bone mineral density in men and women: the framingham study. J Bone Miner Res. 1993;8(5):567-573.
- [Google Scholar]
- Osteoporosis, fractures, and diabetes. International Journal of Endocrinology. 2014;2014:1-10.
- [Google Scholar]
- Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.
- [Google Scholar]
- Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone. 2010;46(5):1226-1237.
- [Google Scholar]
- Bone's mechanostat: a 2003 update. Anat Rec Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology. 2003;275A(2):1081-1101.
- [Google Scholar]
- A review of sarcopenia: enhancing awareness of an increasingly prevalent disease. Bone. 2017;105:276-286.
- [Google Scholar]
- Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res. 2019;31(1):15-17.
- [Google Scholar]
- A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res. 2020;32(2):187-196.
- [Google Scholar]
- A meta‐analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res. 2016;31(5):940-948.
- [Google Scholar]
- A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int. 2012;23(10):2507-2515.
- [Google Scholar]
- Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice. Geriatrics. 2020;5(4):85.
- [Google Scholar]
- Predictors of imminent risk of nonvertebral fracture in older, high‐risk women: the framingham osteoporosis study. JBMR Plus. 2019;3(6)
- [Google Scholar]
- Risk factors for imminent fractures: a substudy of the FRISBEE cohort. Osteoporos Int. 2021;32(6):1093-1101.
- [Google Scholar]
- Imminent fracture risk assessments in the UK FLS setting: implications and challenges. Arch Osteoporosis. 2019;14(1):12.
- [Google Scholar]
- Physical activity and osteoporotic hip fracture risk in men. Arch Intern Med. 2000;160(5)
- [Google Scholar]
- Molecular-based treatment strategies for osteoporosis: a literature review. Int J Mol Sci. 2019;20(10):2557.
- [Google Scholar]
- The effect of alcohol on osteoporosis: a systematic review and meta-analysis. Drug Alcohol Depend. 2019;197:197-202.
- [Google Scholar]
- Impact of cigarette smoking on the risk of osteoporosis in inflammatory bowel diseases. J Clin Med. 2021;10(7):1515.
- [Google Scholar]
- Drugs for the management of osteoporosis: a review. Rev Bras Reumatol. 2011;51(4):379-382.
- [Google Scholar]
- Osteoporosis therapies and their mechanisms of action. Exp Ther Med. 2021;22(6):1379.
- [Google Scholar]
- Effects of resistance exercise on bone health. Endocrinology and Metabolism. 2018;33(4):435.
- [Google Scholar]
- Physical frailty: ICFSR international clinical practice guidelines for identification and management. J Nutr Health Aging. 2019;23(9):771-787.
- [Google Scholar]
- Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011
- [Google Scholar]
- Trunk inclination and hip extension mobility, but not thoracic kyphosis angle, are related to 3D-accelerometry based gait alterations and increased fall-risk in older persons. Gait Posture. 2019;72:89-95.
- [Google Scholar]
- The importance of trunk muscle strength for balance, functional performance, and fall prevention in seniors: a systematic review. Sports Med. 2013;43(7):627-641.
- [Google Scholar]
- Current evidence on the association of dietary patterns and bone health: a scoping review. Adv Nutr. 2017;8(1):1-16.
- [Google Scholar]
- Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96(1):365-408.
- [Google Scholar]
- Annual high-dose oral vitamin D and falls and fractures in older women. JAMA. 2010;303(18):1815.
- [Google Scholar]
- UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporosis. 2017;12(1):43.
- [Google Scholar]
- Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-1045.
- [Google Scholar]
- Spinal compression fracture management: a review of current treatment strategies and possible future avenues. Global Spine J. 2017;7(1):71-82.
- [Google Scholar]
- Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metabol. 2010;95(4):1555-1565.
- [Google Scholar]
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal Osteoporosis<SUBTITLE>A randomized controlled Trial</SUBTITLE>. JAMA. 1999;282(14):1344.
- [Google Scholar]
- ASPEN safe practices for enteral nutrition therapy. J Parenter Enteral Nutr. 2017;41(1):15-103.
- [Google Scholar]
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int : A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2013;24(1):23-57.
- [Google Scholar]
- Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit. Osteoporos Int : A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2018;29(10):2309-2314.
- [Google Scholar]
- Managements of osteoporotic vertebral compression fractures: a narrative review. World J Orthoped. 2022;13(6):564-573.
- [Google Scholar]
- American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2020;26:1-46.
- [Google Scholar]
- Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
- [Google Scholar]
- Osteoporosis: a review of treatment options. P & T : A Peer-Reviewed Journal for Formulary Management. 2018;43(2):92-104.
- [Google Scholar]
- Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632-637.
- [Google Scholar]
- Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy. Front Cell Dev Biol. 2020;8
- [Google Scholar]
- Romosozumab: a novel injectable sclerostin inhibitor with anabolic and antiresorptive effects for osteoporosis. Ann Pharmacother. 2021;55(5):677-686.
- [Google Scholar]
- Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg. 2008;90(Supplement_1):31-35.
- [Google Scholar]
- Targeting WNT signaling in the treatment of osteoporosis. Curr Opin Pharmacol. 2018;40:134-141.
- [Google Scholar]
- The role of sclerostin in bone and ectopic calcification. Int J Mol Sci. 2020;21(9):3199.
- [Google Scholar]
- Lrp4 mediates bone homeostasis and mechanotransduction through interaction with sclerostin in vivo. iScience. 2019;20:205-215.
- [Google Scholar]
- Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286(22):19489-19500.
- [Google Scholar]
- Localization of the gene for sclerosteosis to the van Buchem disease–gene region on chromosome 17q12–q21. Am J Hum Genet. 1999;64(6):1661-1669.
- [Google Scholar]
- The syndromic status of sclerosteosis and van Buchem disease. Clin Genet. 1984;25(2):175-181.
- [Google Scholar]
- Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26(12):2804-2811.
- [Google Scholar]
- Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res : The Official Journal of the American Society for Bone and Mineral Research. 2011;26(12):2804-2811.
- [Google Scholar]
- Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-588.
- [Google Scholar]
- Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone. 2015;81:380-391.
- [Google Scholar]
- Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948-959.
- [Google Scholar]
- Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532-1543.
- [Google Scholar]
- FRAME study: the foundation effect of building bone with 1 Year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res. 2018;33(7):1219-1226.
- [Google Scholar]
- Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417-1427.
- [Google Scholar]
- Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res : The Official Journal of the American Society for Bone and Mineral Research. 2022;37(8):1437-1445.
- [Google Scholar]
- Romosozumab: a first-in-class sclerostin inhibitor for osteoporosis. Am J Health Syst Pharm. 2020;77(23):1949-1956.
- [Google Scholar]
- [Calcimimetics, mechanisms of action and therapeutic applications] Presse Med. 2005;34(15):1095-1100.
- [Google Scholar]
- Therapeutic treatments for osteoporosis—which combination of pills is the best among the bad? Int J Mol Sci. 2022;23(3):1393.
- [Google Scholar]
- Tiliroside, the major component of Agrimonia pilosa Ledeb ethanol extract, inhibits MAPK/JNK/p38-mediated inflammation in lipopolysaccharide-activated RAW 264.7 macrophages. | Sigma-Aldrich. 2016
- [Google Scholar]
- TGFβ-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis. Nat Commun. 2019;10(1):2795.
- [Google Scholar]
- Tiliroside is a new potential therapeutic drug for osteoporosis in mice. J Cell Physiol. 2019;234(9):16263-16274.
- [Google Scholar]
- Wnt signaling pathway in osteoporosis: epigenetic regulation, interaction with other signaling pathways, and therapeutic promises. J Cell Physiol. 2019;234(9):14641-14650.
- [Google Scholar]
- LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513-523.
- [Google Scholar]
- P53 regulation of osteoblast differentiation is mediated through specific microRNAs. Biochemistry and Biophysics Reports. 2021;25
- [Google Scholar]
- WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med. 2013;368(19):1809-1816.
- [Google Scholar]
- The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582-598.
- [Google Scholar]
- Pomiferin exerts antineuroinflammatory effects through activating akt/nrf2 pathway and inhibiting NF-κB pathway. Mediat Inflamm 2022:1-11.
- [Google Scholar]
- Identification of fibroblast activation protein as an osteogenic suppressor and anti-osteoporosis drug target. Cell Rep. 2020;33(2)
- [Google Scholar]
- Advancement in the treatment of osteoporosis and the effects on bone healing. J Clin Med. 2022;11(24):7477.
- [Google Scholar]
- The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.
- [Google Scholar]
- NLRP3 inflammasome: a new target for prevention and control of osteoporosis? Front Endocrinol. 2021;12
- [Google Scholar]
- Can polymorphisms in NLRP3 inflammasome complex Be associated with postmenopausal osteoporosis severity? Genes. 2022;13(12):2271.
- [Google Scholar]
- Copper, lysyl oxidase, and extracellular matrix protein cross-linking. Am J Clin Nutr. 1998;67(5 suppl l)
- [Google Scholar]
- Copper metabolism and cuproptosis in human malignancies: unraveling the complex interplay for therapeutic insights. Heliyon. 2024;10(5)
- [Google Scholar]
- Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway. Signal Transduct Targeted Ther. 2022;7(1):1-3.
- [Google Scholar]
- Copper induces cell death by targeting lipoylated TCA cycle proteins. Science (New York, N.Y.). 2022;375(6586):1254-1261.
- [Google Scholar]
- Identification and immunological role of cuproptosis in osteoporosis. Heliyon. 2024;10(5)
- [Google Scholar]
- Cuproptosis-a potential target for the treatment of osteoporosis. Front Endocrinol. 2023;14
- [Google Scholar]
- Mechanisms of cuproptosis and its relevance to distinct diseases. Apoptosis : An International Journal on Programmed Cell Death. 2024;29(7–8)
- [Google Scholar]
- Cuproptosis and cuproptosis-related genes in rheumatoid arthritis: implication, prospects, and perspectives. Front Immunol. 2022;13
- [Google Scholar]
- Inhibition of osteogenic differentiation of mesenchymal stem cells by copper supplementation. Cell Prolif. 2014;47(1):81-90.
- [Google Scholar]
- Influence of Cu2+ on osteoclast formation and activity in vitro. Int J Mol Sci. 2021;22(5):2451.
- [Google Scholar]
- Effect of copper-doped silicate 13-93 bioactive glass scaffolds on the response of MC3T3-E1 cells in vitro and on bone regeneration and angiogenesis in rat calvarial defects in vivo. Mater Sci Eng C. 2016;67:440-452.
- [Google Scholar]
- Effects of thirty elements on bone metabolism. J Trace Elem Med Biol : Organ of the Society for Minerals and Trace Elements (GMS). 2015;32:86-106.
- [Google Scholar]
- The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease. Biomed Pharmacother. 2023;163
- [Google Scholar]
- Role of exosomal MicroRNAs and their crosstalk with oxidative stress in the pathogenesis of osteoporosis. Oxid Med Cell Longev. 2021;2021
- [Google Scholar]
- Associations of copper intake with bone mineral density and osteoporosis in adults: data from the national health and nutrition examination survey. Biol Trace Elem Res. 2022;200(5):2062-2068.
- [Google Scholar]
- Calcium, iron, copper, boron, collagen, and density changes in bone with aging in C57BL/6J male mice. Exp Gerontol. 1990;25(5):469-481.
- [Google Scholar]
- Roles and mechanisms of copper homeostasis and cuproptosis in osteoarticular diseases. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2024;174
- [Google Scholar]
- Expression, signaling, and function of P2X7 receptors in bone. Purinergic Signal. 2009;5(2):205-221.
- [Google Scholar]
- Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J Bone Miner Res. 2001;16(5):846-856.
- [Google Scholar]
- P2X7Rs: new therapeutic targets for osteoporosis. Purinergic Signal. 2023;19(1):207-219.
- [Google Scholar]
- P2X7 receptors: role in bone cell formation and function. J Mol Endocrinol. 2015;54(2):R75-R88.
- [Google Scholar]
- Deletion of the P2X 7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol. 2003;17(7):1356-1367.
- [Google Scholar]
- The role of the P2X7 receptor on bone loss in a mouse model of inflammation-mediated osteoporosis. Bone Reports. 2017;7:145-151.
- [Google Scholar]
- P2X7 receptor acts as an efficient drug target in regulating bone metabolism system. Biomed Pharmacother. 2020;125
- [Google Scholar]
- NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Investig. 2009;119(10):3024-3034.
- [Google Scholar]
- Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists. Bioorg Med Chem. 2013;21(18):5725-5737.
- [Google Scholar]
- A new family of predicted krüppel-like factor genes and pseudogenes in placental mammals. PLoS One. 2013;8(11)
- [Google Scholar]
- KLF2 regulates osteoblast differentiation by targeting of Runx2. Lab Invest. 2019;99(2):271-280.
- [Google Scholar]
- TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts. PLoS One. 2011;6(4)
- [Google Scholar]
- Krüppel-like factor 3 inhibition by mutated lncRNA Reg1cp results in human high bone mass syndrome. J Exp Med. 2019;216(8):1944-1964.
- [Google Scholar]
- Tanshinol stimulates bone formation and attenuates dexamethasone-induced inhibition of osteogenesis in larval zebrafish. Journal of Orthopaedic Translation. 2015;4:35-45.
- [Google Scholar]
- Adiposity and bone mineral density of Chilean elderly women in relation to toll-like receptor 4 gene polymorphisms. Ann Hum Biol. 2006;33(5–6):585-592.
- [Google Scholar]
- The importance of 8993C>T (Thr399Ile) TLR4 polymorphism in etiology of osteoporosis in postmenopausal women. Ginekol Pol. 2014;85(3):180-184.
- [Google Scholar]
- From osteoimmunology to osteomicrobiology: how the microbiota and the immune system regulate bone. Calcif Tissue Int. 2017;102(5):512-521.
- [Google Scholar]
- The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Targeted Ther. 2022;7(1)
- [Google Scholar]
- YAP promotes osteogenesis and suppresses adipogenic differentiation by regulating β-catenin signaling. Bone Research. 2018;6(1):18.
- [Google Scholar]
- Function of the <scp>SIRT</scp> 3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. Aging Cell. 2017;16(1):4-16.
- [Google Scholar]
- Sirtuin 3 is required for osteogenic differentiation through maintenance of PGC-1ɑ-SOD2-mediated regulation of mitochondrial function. Int J Biol Sci. 2017;13(2):254-264.
- [Google Scholar]
- Sirtuin 3 (SIRT3) maintains bone homeostasis by regulating AMPK-PGC-1β axis in mice. Sci Rep. 2016;6(1):1-10.
- [Google Scholar]

